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General Abstract 
In the last years, tissue engineering (TE) has advanced offering the 
potential for regenerating almost every tissue and organ of the human 
body. Three dimensional (3D) human tissue models can provide a 
good platform for pharmacological screening and drug delivery rather 
than traditional bidimensional (2D) cell culture or animal models. In 
native tissues the extracellular matrix (ECM) promotes the crosstalk 
between cells, and is responsible of several fundamental pato- 
physiological processes. For this reason, tissue engineering is moving 
forward the development of in vitro models in which endogenous 
ECM is present. In the perspective of using in vitro tissues as testing 
platform. Nowadays there is an overlapping between tissue 
engineering and nanomedicine since they share the common 
application to improve the new molecules screening in vitro and the 
pre-clinical testing. Nanomedicine and nanofabrication allow to 
create miniaturized release-based systems such as nano-bio- 
capsulates while novel tissue engineering processess allow to 
building up in vitro tissues and organ mimicking their in vivo 
counterpart. Nanomedicine relies on the fundamental principles of 
tissue engineering as well as the tissue engineering field favors from 
continuous progress in nanomedicine. Indeed, due to the complexity 
of these tissues, studying and analyzing possible strategies to 
implement specific nanocarriers is becoming more and more 
challenging. The big challenge is engenneering capsules able to 
specifically target a certain organ of interest and, then, ensure an 
effective in situ controlled release. 
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The aim of my PhD work is to effectively bridge nanomedicine and 
tissue engineering. Particularly, on the one hand-side, this work 
focused on the realization of functionalized nanoparticles that are 
able to transport lipophilic drug preventing their early degradation. 
On the other side, a 3D intestinal diseased model as a platform for 
drug screening was realized. 
We created nanocapsules starting from an oil-in-water (O/W) 
nanoemulsion coated with a polysaccharide layer film, i.e. a glycol- 
modified chitosan, and subsequently curcumin and paclitaxel were 
loaded. These compounds are usually unlikely water-soluble. In 
particular, curcumin can be involved as a factor for preventive 
therapy while Paclitaxel is included in farmaceuticals for treatment of 
colorectal carcinoma. The final nano-carriers are completely 
biocompatible and biostable. 
In the first part, I investigated the enhancement of the effect of 
curcumin loaded in our system across monolayers of intestinal 
epithelial cells (CaCo-2) in transwell culture. Such in vitro platform 
is suitable for evaluating the functionality of the nano-carrier and its 
specificity towards the mucosal epithelial layer. As an applicative 
example, the investigation of the anti-inflammatory effects exerted by 
the encapsulation of curcumin was carried out. 
In the second part, I developed a more complex in vitro cellular 
model. This is relevant for creating a unique 3D tumoral intestinal 
model capable of mimic physiological in vivo diseased architecture. 
Under these conditions, it was possible to precisely evaluate the anti- 
tumoral effets of paclitaxel in nanocapsules. 
In conclusion, I started from a 2D system to test the internalization 
capability and the efficacy of nanocapsules and then I moved towards 
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the development of a pathological 3D system and implemented the 
aforementioned internalization of nanocapsules loaded with potential 
chemioterapeutics (paclitaxel). 
Effectively, this work contributes to develop a future high throughput 
platform for drug screening of a variety of nano-carriers against 
tumoral-like cellular components. 
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Chapter 1: State of art 
 
 
Tissue engineering meets nanomedicine 
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Introduction 
 
The main function of the small intestine is the absorption of essential 
nutrients, water and vitamins. Moreover, it constitutes a barrier 
protecting us from toxic xenobiotics, pathogens and drugs. For a 
better understanding of these processes, the development of a valid 
intestinal in vitro model as a platform for drug delivery is necessary 
for more accurate pharmacological and pathological investigation 
such as transport mechanisms and barrier function. 
 
1.1 Intestinal epithelium: structure and function 
 
Human small intestine, which includes the duodenum, jejunum and 
ileum, is a convoluted tube that is, on average, 2.5 cm in diameter 
and 3 m long [1] The human small intestine possesses highly 
complex 3D microenvironments that achieve the maximum 
efficiency of absorption thanks to the presence of circular folds and 
villi (Figure 1.1a). The small intestine submucosa and mucosa form 
valvulae conniventes or Kerckring’s folds that protrude into the 
lumen transversely and increase the retention time of chyme. These 
permanent ridges, begin to appear near the proximal portion of the 
duodenum and disappear nearly completely in the distal ileum. [2] 
On the surface of these structures there are some protrusions known 
as intestinal villi. Each villus is about 0.5 mm high and there are 30 
villi per mm2 (Figure 1.1b). [1-3] Between each villus there are the 
invaginations named crypts. Intestine stem cells can differentiate into 
four different intestinal epithelial type of cells, which are the 
enterocyte or absorptive cells, goblet, enteroendocrine and Paneth 
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cells. Although Paneth cells reside within the stem cell niche at the 
bottom of the crypt, the other three types of intestinal epithelial cells 
migrate toward the tip of the villus, forming a columnar epithelial 
monolayer that covers the intestinal mucosa. The crypt and villus 
structures generate chemical gradients that affect the epithelial cell 
physiology. On the basolateral surface there is the blood flow. In the 
lumen there are also many commensal bacteria with a density 
increasing from 103 organisms per ml of luminal contents in 
duodenum to 109 per ml of luminal contents in the distal ileum. [4] 
Within this dynamic and complex environment, the small intestine 
epithelium has the most vigorous renewal process in adult epithelial 
tissues, with the epithelial monolayer regenerating every 5 days. 
 
 
 
 
 
b) c) 
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Figure 1.1:a) Illustration of human small intestine epithelium on 
crypt–villus axis. Adapted from [1] b) SEM of human small intestine villi. 
Stereo pair scanning micrographs showing a group of villi. The great depth 
of focus of the sem is clearly demonstrated. Epithelial cells (EP), globet cell 
orifices (G), corrugations (C), crypt mouths (CM) and mucus (M) 
COPYRIGHT ref [3]. c) Continuous cell-cell contact is made at the apical 
end of the lateral interspace where a ring of bidirectional actin filaments is 
concentrated Adapted from [5] 
 
 
The fundamental function of the intestinal epithelium is to act as a 
barrier that limits interactions between luminal contents such as the 
intestinal microbiota, the underlying immune system and the 
remainder of the body, while supporting vectorial transport of 
nutrients, water and waste products. [5] Epithelial barrier function 
requires a contiguous layer of cells as well as the junctions that seal 
the paracellular space between epithelial cells. Epithelial cell layers 
are interconnected by tight junctions (TJs), which are localized within 
apico-lateral membranes. The proteins that form TJs are regarded to 
provide a static barrier, determining epithelial properties. 
Compromised intestinal barrier function has been associated with a 
number of disease states, both intestinal and systemic. [6] The 
intestinal epithelium forms an important physiological barrier in the 
gastrointestinal (GI) tract but this barrier can be compromised by a 
wide range of substances including drugs, microbes, and dietary 
disorders including inflammatory bowel disease and in the other 
cases colon rectal cancer. For this purpose, a lot of in vitro models 
have been developed in order to understand the drug absorption and 
trasport. [7] 
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1.2 Realization of the intestinal epithelium 
equivalent in transwell as a platform for drug 
delivery test: from 2D to 3D models 
The first in vitro intestinal epithelium that marked a promising 
passage from 2D model to 3D model, was realized for detailed 
studies of drug transport by using cultured monolayers of epithelial 
cell lines grown on semipermeable membranes called 
Transwell.(Figure 1.2) [8-9] 
These cells, known as CaCo-2, a human colon carcinoma cell line, 
which exhibits features similar to human intestinal epithelium, are 
able to form a confluent enterocytes-like cells [10] and for this 
purpose are used for in vitro studies. CaCo-2 model has been 
developed as a powerful in vitro tool in the early assessment of 
human drug permeability and is even approved by regulatory 
agencies for biowaver applications (i.e. in vitro tests in lieu of in vivo 
animal experiments). CaCo-2 cells represent a more formidable 
barrier to drug absorption than the upper regions of the intestine, 
which is where the majority of oral drugs permeate into the body. 
The first study attempting to correlate passive drug permeability in 
CaCo-2 monolayers with drug absorption in humans after oral 
administration suggested that the cell monolayers might be used to 
identify drugs with potential absorption problems. [11] Many 
researchers have sought to improve upon the existing unicellular 
model. It is hoped that this will result in a more relevant and 
predictive model for researchers to test new drugs but also to dissect 
cellular cross talk and to probe cell-matrix interactions. 
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Transwell systems are based on a porous polystyrene (PET) or 
polycarbonate (PC) membrane to study of transport mechanisms 
across the intestinal epithelial barrier as well as the investigation of 
the influence of target substances on barrier integrity. However, this 
artificial setup reflects only limited aspects of the physiology of the 
native small intestine and can pose an additional physical barrier. The 
2D in vitro small intestine model has been widely recognized as a 
very useful screening tool that has not only greatly reduced animal 
use but also facilitated the drug discovery and preclinical 
development processes. 
 
 
 
 
 
Figure 1.2: Transwell permeable support: Caco-2 monolayer 
grown on a permeable filter support. 
 
The succesful promotion of a commercial drug requires significant 
speculation of time and financial resources wherein latestage failures 
become a reason for catastrophic failures in drug discovery. 
The innovation in technologies, need to give reliable prediction of 
efficacy, and more importantly, toxicology of the compound early in 
the drug discovery process before clinical trials. 
In vitro studies still require an improvement of in vitro-in vivo 
correletions and for this purpose, due to their ability to mimic spatial 
and chemical attributes of native tissue, (3D) tissue models have 
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demonstrated to provide better results for drug screening. However, 
in vivo cells reside in a 3D environment surrounded by other cells and 
the ECM that play an important role in a living tissue. Recent studies 
indicated that cell-cell interaction and cell-extracellular matrix 
communications are key factors between 2D and 3D system as well 
as between different 3D systems. [12]. The majority of existing cell- 
based drug assays utilizes the 2D monolayer culture method in which 
cells are attached on flat or rigid substrate comprised of glass or 
polystyrene. In this condition, cells proliferate at a rapid rate to a 
sheet-like confluency but cannot replicate the microvillus 
polarization. The absorptive surface in terms of area is not enough for 
a valid predictive studies. However, owing to their inability to 
achieve the complexity of in vivo cell and tissue organization, they do 
not adequately recapitulate healthy phenotype. 
Animal models also fail to recapitulate much of human physiology 
and disease. [13] Because of the importance of the gastrointestinal 
(GI) tract to health and disease, many in vitro and in vivo animal 
models and human tissue models of the GI tract have been developed. 
[14-16] 
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1.3 Tissue engineering (TE) for drug delivery 
 
Over the last years, Tissue Engineering (TE) has established in the 
biomedical and scientific scenario as a new emerging field consisting 
of several interdisciplinary applications that combine the principles 
and methods of life science with those of engineering, aiming at 
repairing or regenerating portions or of whole biological tissue and 
organs (bone, cartilage, bladder, skin, cornea, blood cells, muscle, 
liver, pancreas, intestine, etc.). [17-20] The purpose of TE research is 
very clear: establishing a new clinical technology that makes possible 
medical applications for diseases that have been too difficult to be 
cured by existing methods. Initially, it was thought that the principles 
of TE could be applied only virtually, but today it is known that many 
applications are widely used not only in tissue regeneration but also 
in the industrial field. [21-22] The biological environment is made up 
of cells, cellular signaling and ECM. The cells are the core of the 
tissue for istance, to explicate their funtions they require an adequate 
system of signal transduction. The ECM is composed also of collagen 
and elastin fiber network synthetized by the cells themselves and 
secreted in the extracellular space. Single cells, without a three-
dimensional guide, are indeed not able to organize themselves in a 
3D tissue with its complex architecture, since the only cell 
proliferation is not sufficient. Single cells need a 3D support, defined 
as “scaffold”, whose main function is to support and control cellular 
processes, as well as proliferation, differentiation and synthesis of 
organic molecules and mediators, known as growth factors, which act 
in an autocrine and paracrine pathways on cellular processes. [23] 
As shown in literature, the first 3D tissue models 
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reproduced in vitro were those which are frequently injured [24] as 
skin, cartilage or bone. In contrast there are other tissues (e.g gut, 
liver, cervix) which are enginereed for the investigation of organ 
targeting, drug delivery and drug screening. 
 
1.3.1 In vitro 3D intestinal models: from 
decellularized animal scaffold models to artificial 
topography models 
There are a lot of intestinal epithelial in vitro platforms used for drug 
delivery systems that replaced the conventional 2D in vitro models 
like transwell model. One of these is the reproduction of a 3D small 
intestine created in vitro by utilizing decellularized small animal 
intestine segments. [26] For example, CaCo-2 cells and human 
microvascular endothelial cells were cultured on the apical and 
basolateral sides of a decellularized porcine jejunal scaffold. [27] 
Biological scaffolds from decellularized tissues currently offer the 
highest comparability to tissues in vivo. Among these scaffolds, the 
BioVaSc-TERM®, a decellularized porcine gut segment, 
demonstrated to be applicable as a platform for the generation of 
various tissues equivalents. [28] Hence, the scaffold can be used to 
generate vascularized tissue equivalents by reseeding the vessels with 
human endothelial cells and the subsequent perfusion using 
bioreactor systems. [29] The BioVaSc-TERM® has already been 
tested as a vascularized implant in preclinical studies and employed 
as an autologous airway patch. [30] However, since the scaffold is 
complex and not all features are needed in mid- or high-throughput 
testing strategies, the BioVaSc-TERM® need to be adapted to the 
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requirements of in vitro drug testing. [31] Walles et al. also 
developed an alternative primary human small intestinal tissue 
model. This novel approach combines previously established gut 
organoid technology with a natural (ECM) based on porcine small 
intestinal scaffold (SIS). Intestinal crypts from healthy human small 
intestine were expanded as gut organoids and seeded as single cells 
on SIS in a standardized transwell-like setting. [32] Additionally, a 
decellularized rat intestinal scaffold with villus–crypt structures and 
vasculature has been obtained by using detergent–enzymatic 
treatment, and its potential for recreating functional intestine tissue 
was demonstrated. [33] In particular, reducing animal testing in drug 
development, is one of the first aim for the scientists. Furthermore, 
the requirement of using animal tissue makes these methods less 
practical for preclinical drug studies than other in vitro models. 
Animal models also fail to recapitulate much of human physiology 
and diseases. In the last two decades with the development of 
microfabrication and other biomaterials, fabrication techniques, 
biomimetic topography has been integrated into in vitro intestinal 
models to represent human small intestine 3D features. The artificial 
topography for reproducing 3D small intestine models has been 
largely developed. Indeed, through the use of photolithography, 
human small intesine crypte were ribuild. [34-35] Wang et al., 
suggesting that the influence of micron-scale (100mm) crypt-like 
micro-well topography on intestinal cell behavior it is important to 
determine whether the unique topography of intestinal crypt-villus 
unit plays an important role in regulating intestinal cells. [36] CaCo-2 
cells were cultured on poly-dimethylsiloxane (PDMS) substrates with 
biomimetic topography (micro-well arrays). It was found that 
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intestinal crypt-like topography affects CaCo-2 spreading, migration, 
metabolic activity, as well as cell differentiation. This study 
outcomes the influence of topography substrates on cells. Elements 
for biomimetic scaffolds can be ultimately designed for intestinal 
tissue engineering. Compared with 2D flat substrates (Figure 1.3), 
CaCo-2 cultured on PDMS substrates with crypt-like topography 
exhibited higher mitochondrial activity and lower alkaline 
phosphatase activity like in vivo. [37] Wang et al. published another 
study where a biomimetic intestinal cell culture system composed of 
type I collagen based permeable cell culture membranes 
incorporating both micron-scale intestinal crypt-like topography and 
nanometer scale topography was fabricated. In this case, 
transepithelial electrical resistance (TEER) values were found to be 
slightly lower for CaCo-2 monolayers cultured on topographically 
modified collagen membranes relative to flat collagen controls, 
suggesting that crypt-like topography might affect tight junctions of 
the CaCo-2 monolayer. [38] 
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Figure 1.3. CaCo-2 cultured on PDMS substrates with crypt-like 
topography: F-actin staining (A,B,C) and SEM (D,E,F) of Caco-2 
cells interacting with 50 mm well structures as they spread across the 
wells, 24 h after initial seeding. The scale bar corresponds to 25 mm. 
[Adapted from Wang et al., 2009] 
 
Wang et al. (Figure 1.3) utilized to build up villus scaffolds is 
poly(lactic-co-glycolic acid) PLGA, but porous PLGA villous 
structures had considerably larger basal areas than human small 
intestine vill, however owing to the resolution limitation of this 
technique, could not represent dimensions and density of villi 
relevantly. [39] Sung et al showed that, by combining laser ablation 
and sacrificial molding techniques, a collagen villous scaffold was 
fabricated with 0.5 mm villous height and 25 villi per mm2 density, 
with striking similarity to the human jejunal villi. [40] They proposed 
a hydrogel scaffold mimicking the microscale 3-D geometries of 
biological tissues. This method offers several advantages over 
currently existing methods for microfabrication of hydrogels. Using 
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alginate as a sacrificial layer is particularly advantageous since the 
alginate dissolving process is physiologically mild, and therefore 
compatible with applications involving cell (Figure 1.4). Although 
the collagen scaffold did not exhibit variable transport characteristics 
for different small molecule drugs, the scaffold itself became a 
significant transport barrier for the rapidly absorbed drug antipyrine, 
which is absorbed through a transcellular pathway. Hence, this 3D 
model not be used to test a wide range of drugs with broad 
permeability coefficients. Ingeber et al. demonstrated that the 
engineered villi exhibit specialized cell and tissue functions, 
including elevated mucus production and enhanced CYP3A4 drug 
metabolizing activity (Figure 1.5). 
Another type of 3D model consists of multiple layers of relevant cell 
types, including a flat monolayer of Caco-2 on a gel containing 
dendritic cells or macrophages. [41] Generally, to form these models, 
a thicker layer of collagen protein matrix than used on conventional 
2D models was coated on a cell culture insert. Although the flat 
collagen matrix does not capture structural features of the small 
intestine 3D microenvironment, the integration of immune 
components in the collagen matrix makes this model a useful in vitro 
tool for studying inflammatory bowel diseases. 
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A) 
B)  
 
Figure 1.4 Hydrogel scaffold mimicking the microscale 3-D 
geometries of biological tissues: A) Overall fabrication process. The 
first plastic mold is created by laser ablation, from which the PDMS 
reverse-mold is created. The alginate second mold is made from the 
PDMS, and dissolved after the final hydrogel structure is made. B) Colon 
carcinoma cell line, Caco-2 cells, was seeded onto the structure and 
cultured for 3 weeks until the whole structure was covered, forming 
finger-like structures mimicking the intestinal villi covered with epithelial 
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cells. Reproduced from [37] with permission from the Royal Society of 
Chemistry. 
 
 
 
 
 
 
 
Figure 1.5: Formation of intestinal villi by CaCo-2 cells within in 
Gut-on-a-Chip cultures. (A) Schematic showing transformation of a 
planar intestinal epithelium into villus structure (top) and corresponding 
phase contrast images of CaCo-2 cells that undergo similar villus 
morphogenesis recorded at 50 and 100 h (bottom). (B) A 3D 
reconstruction of Z-stacked images of CaCo-2 villi stained for nuclei 
(blue), F-actin (green), and mucin 2 (magenta) is shown at the left. SEM 
images of these villi are shown at the middle and right at low and high 
magnification, respectively. (C) Schematics showing a vertical cross 
section and horizontal cross sections at the tip (T) versus middle (V) of a 
single villus are shown at the left. Immunofluorescence confocal views of 
CaCo-2 villi shown at the right demonstrate staining for the tight junction 
protein, ZO-1 (red) in vertical (top) versus horizontal en face sections of  
a CaCo-2 villus (bottom left). Bottom right view shows staining for the 
continuous apical brush border membrane labeled for F-actin (green) 
overlying the well oriented intestinal cell nuclei (blue). All scale bars are 
25 mm, except right SEM image ( scale bar, 10 mm). Reproduced from 
[42] with permission from the Royal Society of Chemistry. 
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1.3.2 In	  vitro	  3D	  culture	  systems	  for	  drug	  
delivery	  
	  
In vitro test systems gain increasing importance in preclinical studies 
to increase the predictivity and reduce animal testing. Herein, barrier 
tissues are particularly interesting as they are the guards of human 
body. These barriers are formed by highly specialized tissues such as 
skin, lung,and gut. However, to recapitulate these tissues researchears 
are currently restricted by a lack of suitable models. Pharmaceuticals 
have to pass several preclinical studies in order to advance into 
clinical trials. Thee tests include in vitro and in vivo models to predict 
drug delivery, toxicity, and efficacy. Many drugs fail in the clinical 
studies due to poor bioavailability and nonspecific targeting, 
demonstrating the need for more predictive test systems. [42] 
Especially drug delivery is difficult to model in different species or 
cell culture models. The small intestine combines transport and 
barrier function within a simple columnar epithelium. [43] 
In addition most substances have to pass the ECM, to enter in the 
blood stream. In addition, most substances have to pass the 
extracellular matrix to enter the bloodstream. While there is a wide 
array of in vitro or ex vivo tests available, most standard assays 
employ only simple 2D cell cultures. These test systems lack key 
features, such as polarization and differentiation of the barriers as 
well an extracellular matrix, leading to very low-barrier functions. It 
was shown that the matrix underlying the epithelium has a strong 
influence on the epithelium architecture and on the transport of 
substances. [44-45] Due to the low in vitro-in vivo correlation of 
many current models, these test systems are limited in their 
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predictions, which can lead to false results for drug delivery in the 
human body. [46] To address these pitfalls, tissue models containing 
a well differentiated and functional epithelium and a physiological 
scaffold are needed to create predictive 3D test systems. Through the 
advances in tissue engineering and material science, a broad variety 
of scaffolds mimicking the extracellular matrix have been introduced. 
Synthetic scaffolds such as porous polystyrene or polycarbonate 
membranes are easy to fabricate but lack physiological features. 
Collagen or matrigel hydrogels include the main proteins of the 
human tissue, but introduce some with disadvantages such as 
mechanical instability and contraction through fibroblast mediated 
remodeling. [47] 
 
1.4 Nanomedicine and drug delivery: different 
carriers and approach 
Nanomedicine and drug delivery have opened a new horizon of 
possibilities and strategies, particularly for controlled release and 
diagnostic. Drug delivery describes a process whereby a therapeutic 
agent is administrated to the body in a controlled manner. Drug 
delivery technologies make medicine more convenient and 
acceptable to a patient by simplyfing the dosing regimen and 
improving administration. [49] 
During the last decades many nanocarriers have been realized. 
Everyone with an increasingly refined strategy. 
More recently researcher focused on the development of 
“multifunctional” platforms, i.e. nano-vectors able to simultaneously 
or sequentially perform several functionalities: 
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• controlled degradation 
• controlled drug release 
Another important goalof this research activitiy, is the realization of a 
completely biocompatible and biodegradable nanocarrier. In 
particular, the main objective is the realization of nanometric sized 
drug vehicles, derived from natural materials, but holding the features 
needed for the drug delivery. In fact, the oil core carrier is built up 
with natural materials like soybean oil and egg lecithin and able to 
encapsulate hydrophobic drugs, like curcumin, paclitaxel, or some 
others benefical oils- like almond and bergamotto oils. 
 
1.4.1 Monolayer deposition based on Layer by 
Layer technique 
 
The layer-by-layer (LbL) deposition technique is a versatile approach 
for preparing nanoscale multimaterial films. 
In particular, it is a versatile and robust technique for fabricating 
customized thin films of diverse composition. [50-52] 
It provides a high level of control on properties such as thickness, 
composition and nanostructure. [53-54] The method has 
predominantly been used to assemble films using electrostatic 1-4 
hydrogen-bonding [55-56] interactions or electrochemical deposition 
[57-58] and, recently, to fabricate polyelectrolyte multilayer capsules. 
[59] The latter ones have attracted widespread interest in the field of 
drug delivery due to their control in the preparation procedure and 
their multifunctional features. [57-61] In addition, polyelectrolytes 
are also emerging as bio-functional interfaces in tissue engineering. 
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[60] However, the main forces stabilizing LbL assembled systems are 
based on electrostatic interactions, making such systems very 
sensitive to environmental conditions, such as variations in the ionic 
strength or temperature of the medium, and thus susceptible to 
disassembly [61-62] which represents an important limitation for 
some biomedical applications. 
 
1.4.2 O/W nanoemulsion 
 
The development of nano-carriers capable of conveying and releasing 
bioactive substances is currently creating great interest and it is 
becoming one of the most important objectives of, above all, food, 
cosmetics and pharmaceutical industries. Oil-in-water (O/W) nano- 
emulsions, consisting of small lipid droplets dispersed in an aqueous 
medium, can besuitable as the basis of many kinds of foods (e.g., 
milk, cream, beverages, dressings, etc.), [63-64] as well as cosmetics 
(lotions, transparent milks, and crystal-clear gels). [62-65] Their 
ability to dissolve large quantities of hydrophobics and protect their 
cargo from hydrolysis and enzymatic degradation makes nano-
emulsions ideal vehicles for the purpose of drug delivery. O/W nano-
emulsions represent an ideal nano-carrier to conveying and releasing 
powerful poorly water-soluble drugs. [65-67] The covalently bound 
multilayer resulted to have an increased biostability, for both PS NPs 
and, more interestingly, O/W nano- emulsions templates. Moreover, 
the possibility to perform the cross- linkage without any 
photoinitiator, as demonstrated through cytotoxicity assays, and the 
choice of natural and biodegradable 
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components makes this approach highly biocompatible and efficient 
in the field of bio-applications. 
 
1.4.3 Polysaccharides-based polyelectrolyte 
layers 
 
Polysaccharides are natural polymers that belong to the family of the 
carbohydrates and play fundamental roles in many biological 
contexts. Their structure is made of sugar rings linked by glycosidic 
bonds and various side functions. These highly abundant molecules 
are from various origins including algal origin (e.g. alginate and 
carrageenan), plant origin (e.g. cellulose, pectin and guar gum), 
microbial origin (e.g. dextran and xanthan gum), and animal origin 
(e.g. chitosan, hyaluronan, chondroitin and heparin). Naturally 
occurring polysaccharides are diverse in their physicochemical 
properties. They possess multiple chemical structures (Figure 1.6) 
and the chemical composition greatly varies, as well as the molecular 
weight (Mw) and ionic nature. This versatility also contributes to a 
wide range of biological activities. From a pharmaceutical standpoint, 
polysaccharides possess many favourable characteristics such as low 
toxicity, biocompatibility, stability, low cost, hydrophilic nature and 
availability of reactive sites for chemical modification. Two elements 
are of utmost importance in the chemistry of polysaccharides. Firstly, 
the glycosidic bonds can be the target of glycoside hydrolase 
enzymes and can thus be biodegraded relatively easily. Secondly, the 
side groups can directly affect the polysaccharide charge density, 
hydration and chemical reactivity, and can also be responsible for the 
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formation of secondary structures. When charges are present, 
polysaccharides behave like polyelectrolytes. The negative groups 
(COO−) with pKa around 3–5 or sulfate groups (SO3−) with a pKa  
of around 0.5–1.5.32 The positively charged groups are ammonium 
groups (NH3+) with a pKa of around 7–10.33, 34. In particular, the 
presence of negative and positive groups makes these polymers 
suitable for LbL application. [68] Indeed, Polyelectrolyte Multilayer 
(PEM) films give rise to self-assembly via LbL, because of both 
interactions between the negative and positive groups and the 
entropic gain associated with these interactions. In addition, the 
presence of carboxylic and ammonium group makes these polymers 
suitable for chemical modifications. However, certain difficulties are 
encountered when working with polysaccharides. Chemical 
modification can be a real challenge because of the high hydration 
shell and poor solubility in organic solvents. 
Due to their lower solubility, pH and ionic strength can only be 
varied to a lower extent than for their synthetic counterparts. [69-70] 
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1.4.4 Chitosan modified Glycol Chitosan and 
thyolated glycol chitosan 
Chitosan (CT) and glycol chitosan (GC) are linear polysaccharides 
composed of β-(1,4)-linked D-glucosamine and N-acetyl-D- 
glucosamine (Figure 1.6). Even though the discovery of chitosan 
dates from the 19th century, it has only been over the last three 
decades that this polymer has received attention as a material for 
biomedical and drug delivery applications. [68-72] The accumulated 
information about the physicochemical and biological properties of 
chitosan led to the recognition of this polymer as a promising 
material for drug delivery and, more specifically, for the delivery of 
delicate macromolecules. [73] CT is obtained by deacetylation from 
chitin, a highly abundant polysaccharide, which is the main 
component of the crustaceans and insect exoskeleton, and certain 
fungi. [74] Due to the limited solubility of chitin in aqueous 
solutions, chitosan is more suitable for industrial applications. [75] 
Whereas chitin is a polymer of N-acetyl-D-glucosamine units, 
chitosan is less easily defined in terms of its exact chemical 
composition. It usually refers to a family of polymers that are 
characterized by the number of sugar units per polymer molecule 
(n+m), which defines the molecular weight, and the degree of 
deacetylation (DD). The DD affects the pKa34 and, consequently, the 
solubility of chitosan in aqueous solutions, making the polymer 
soluble in acidic solutions and insoluble in neutral or in weak alkaline 
solutions. [76] The intriguing properties of CT have been known for 
many years and the polymer has been used in the fields of 
agriculture, industry and medicine. [77, 79] In particular, the 
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pharmaceutical and biomedical applications of CT probably offer the 
greatest promise. [78-81] CT lacks irritant or allergic effects and is 
biocompatible with both healthy and infected human skin.[80] When 
chitosan was administered orally in mice, the LD50 was found to be 
in excess of 16 g/kg, which is higher than that of sucrose. CT is 
approved for dietary applications in several country and it has been 
approved by the FDA for use in wound dressings.[ 82] Due to its 
protonable amine groups, CT has a polycationic nature and, therefore, 
is able to form PEM films. Actually, the choice of a polycationic 
polysaccharide is very limited. In fact, only chitosan is currently 
available and used in PEM films. [72] Due to its aforementioned 
numerous interesting properties, chitosan is probably by far the most 
widely used polysaccharide in LbL film.[71] Its positive charge also 
facilitates adhesion to mucosal surfaces, which are mostly negatively 
charged. [72] In addition, the amine groups can be also used for 
chemical modifications. The main problems concerning chemical 
modification of the amine group are (i) the difficulty to perform any 
modification with a limited pH working range and (ii) the reduced 
solubility of the modified chitosan in water due to the loss of free 
amine groups. Several attempts were made to improve the water 
solubility of CT, but most of them also reduce the fraction of free 
amine groups. On the other hand, a different modification of chitosan 
was proposed to obtain a polymer with improved water solubility but 
with no reduction of free amine groups. GC owes its water solubility 
to the incorporation of the hydrophilic glycol group, introduced by 
reacting chitin with ethylene oxide followed by its deacetylation. [75] 
For these reasons, GC could represent a valid alternative to CT for 
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the realization of PEM films, in particular when modified polymers 
are required. (Figure 1.7) 
Another modification of chitosan with a thiolation agent, the N- 
acetyl-L-cysteine (NAC), through an amidation reaction with a water 
soluble carbodiimide as condensing agent (EDC, ethyl-3-(3- 
dimethylaminoisopropyl)-carbodiimide) and 1-hydroxy-1,2,3- 
benzotriazole (HOBt) as additive. (Figure 1.8) 
Polymer characterization was performed with 1H NMR spectroscopy 
and the degree of functionalization was determined using the 
colorimetric Ellman’s test. 
 
 
 
 
 
 
 
Figure 1.6. Chemical structure of chitosan. CT is a linear 
polysaccharide composed of β-(1,4)-linked D-glucosamine (n) and N- 
acetyl-D-glucosamine (m). The relative abundance of the acetylated 
or deacetylated forms can be expressed in percentage as Degree of 
Acetylation (DA) or Degree of Deacetylation (DD). The amine group 
of D-glucosamine results to be positively charged in acidic media 
making chitosan a polycation. 
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Figure 1.7. Chemical structure of glycol chitosan. GC is a 
modified chitosan with a glycol group linked to the hydroxyl in 
position 6 of the sugar ring. 
 
 
 
 
 
Figure 1.8. Chemical structure of Thiolated Glycol Chitosan 
(GC-NAC), is a modified glycol chitosan with the thiolated group on 
the deacitilated position. 
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1.5 Encapsulated nutraceuticals and drugs in 
O/W nanoemulsions 
 
1.5.1 Curcumin 
 
 
Curcumin is one of the two drugs of interest which have been 
investigated in my Phd thesis. It was encapsulated in an oil-in-water 
(O/W) nanoemulsion, for its poor stability. It is a natural component 
of the rhizome of turmeric (Curcuma longa) and one of the most 
powerful antiinflammatory agents. In many chronic illnesses in 
which inflammation plays a major role, curcumin has shown various 
therapeutic potentials such as anti -inflammatory and antioxidant 
properties. [84] Natural polyphenols have largely used for prevention 
and treatment of several disorders due to their antioxidant, anti- 
inflammatory effects. In contrast one of the main disavantages of 
their free administration is its low bioavailability. They show 
lipophilic nature and poor stability in aqueous solutions [85] resulting 
in low efficiency via oral administration. [86] Thus, different 
formulations were designed for the improvement of bioavailability of 
these compounds. [87-88] 
Recently, we implemented a high performance nanocarrier system, 
capable of loading and protecting curcumin degradation. A selective 
coating on the nanoparticles enhances the bioavailability of 
curcumin. 
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1.5.2 Paclitaxel 
 
 
The second drug explored in my thesis is paclitaxel (PXL). It is 
largely used as chemotherapic agent that has been used clinically for 
many years to treat ovarian, breast, lung, and pancreatic cancer. 
Recent studies showed the effects of PXL also in colon rectal cancer. 
The mechanism of action of PXL involves interference with the 
process of normal breakdown of microtubules during cell division, 
causing apoptosis in the treated cells. Furthermore, PXL acts as 
inhibitor in tumoral cells during glutaminolysis-related gene 
expression. [90-91] In the light of this, we tested the effect of 
encapsulated PXL on 3D tumoral systems and we evaluated its 
inhibiting properties. 
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Chapter 2 
 
 
 
 
“In Vitro Study of Intestinal  Epithelial  
Interaction with Engineered Oil in Water 
Nanoemulsions Conveying Curcumin” 
 
 
 
 
 
 
 
 
 
 
 
 
Adpted from Langella et al, 2017 “In vitro study of intestinal 
epithelial interaction with engineered oil in water nanoemulsions 
conveying curcumin”, submitted manuscript. 
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Abstract 
 
The development of innovative nano-bio-encapsulation systems 
continues to be an area of intense activity as the demand of improved 
delivery systems is constantly increasing in several fields including 
nanomedicine. For this purpose, an important goal is carrying out 
appropriate engineering of the surface of these nano-carriers to  
satisfy the organ target features for an effective in situ release and 
elucidate the mechanism of action which most of the time is 
neglected. Here, an oil-in-water (O/W) nanoemulsion coated with a 
polysaccharide layer film - i.e. a glycol chitosan modified with a thiol 
moiety - was used as nano-carrier to convey a powerful poorly water- 
soluble nature based drug, curcumin. The final nano-carrier was 
completely biocompatible and bio-stable. We investigated the 
enhancement of the effect of curcumin loaded in our system across 
monolayers of intestinal epithelial cells (CaCo-2) in transwell culture. 
Such in vitro platform resulted suitable to evaluate the functionality 
of the nano-carrier and its specificity towards the mucosal epithelial 
layer and, as applicative example, to investigate the anti- 
inflammatory effects exerted by the encapsulation of curcumin. 
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2.1 Introduction 
 
 
The use of molecules or food ingredients with positive effects on 
health, prevention and treatment of diseases is increasingly in 
demand. [92] However, many nutraceuticals are unstable or poorly 
water soluble and their oral administration results to be limited. [93] 
The development of suitable carrier systems for oral delivery remains 
a major challenge for biomedical scientists and bioavailability 
remains limited even in the case of nano-encapsulation. As a 
consequence, oral formulations must be designed to preserve the drug 
from gastric absorption and improve its interaction with the intestinal 
tract. 
An example of a powerful nutraceutical whose potentiality is not yet 
fully exploited is the curcumin. Among the naturally derived 
therapeutic products, curcumin, [1,7-Bis(4-hydroxy-3- 
methoxyphenyl)-hepta-1,6-diene-3,5-dione] is one of the most 
extensively studied in recent decades, due to its various properties. In 
many chronic illnesses in which inflammation plays a major role, 
curcumin has shown various therapeutic potentials such as anti- 
inflammatory and antioxidant properties. [94] In fact, molecular 
studies have indicated that curcumin blocks the activation of factors, 
such as cytokines, a class of enzymes present in human cells and able 
to trigger the inflammatory response. [95] Despite these attractive 
properties, curcumin has a very limited bioavailability because of its 
lipophilic nature and its poor stability in aqueous solutions [96] 
resulting in a low efficient oral administration. [97] 
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We recently proposed a high performance nanocarrier system, 
capable to load and protect curcumin from degradation and to 
enhance its bioavailability due to a coating with a thiol-modified 
chitosan. [98] It was demonstrated how important are the impact of 
some parameters such as size and degree of surface modification by 
direct evaluation of effects such as bioavailability, in in vivo anti- 
inflammation. However, while in vivo studies provide a direct proof 
of the validity of a drug delivery system, appropriate in vitro studies 
are necessary in order to specifically elucidate the mechanism of 
passage through the intestinal barrier. Nonetheless, there is an urgent 
need of highly fast, reliable and cost-effective in vitro models to 
predict intestinal absorption in order to reduce, refine or replace in 
vivo experimentation. [99] The intestine epithelial barrier is the first 
barrier and the most important location for the nutraceuticals coming 
from the lumen of the gut. The transport of drugs across the intestinal 
epithelium may occur by one, or more than one, of four different 
routes: the passive transcellular and paracellular routes, the carrier 
mediated route and by transcytosis. [100] Here, in order to 
comprehensively understand the route of the nano-system carrying 
the curcumin and the biochemical effect of the drug release, an air 
liquid interface (ALI) of CaCo-2 cells in transwell was effectively 
reproduced [101-104] and used as an in vitro testing platform. As 
previously reported, [105] the human CaCo-2 cells differentiate, after 
their polarization in culture, forming monolayers of mature intestinal 
enterocytes which can be used as a model that reproduce the 
intestinal barrier for in vitro prediction of intestinal drug absorption 
transport and toxicology studies. By using this model, we were able 
to demonstrate the interaction route and the biosafety of nanocarriers 
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in terms of cell viability and tight junction integrity as well as the 
curcumin bioavailability and its antioxidant effect on LPS-treated 
intestinal mucosa. Our results demonstrate that the proposed nano- 
carrier represents a very promising tool for the effective release of 
unstable and poorly water-soluble drugs. 
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2.2 Materials and methods 
 
2.2.1 Materials 
 
1-hydroxybenzotriazole hydrate (HOBt), n-acetyl-L-cysteine (NAC), 
Rhodamine B isothiocyanate (RBITC), paraformaldehyde and 
curcumin (from Curcuma Longa (Turmeric), powder, m.w. = 368.38 
g/mol) were purchased from Sigma-Aldrich. Glycol chitosan was 
purchased from Wako Chemicals. 1-(3-dimethylaminopropyl)-3- 
ethyl-carbodiimide hydrochloride (EDC) was purchased from Iris 
Biotech. CaCo-2 cells were obtained from American Type Cell 
Culture (ATCC, Usa). Dulbecco’s Modified Eagle’s Medium 
(DMEM, Gibco, Life Technologies), supplemented with 10% fetal 
bovine Serum (FBS, Sigma Aldrich), 1% penicillin/streptomycin and 
1% L-glutamine (Lonza, Milan) and 2% nonessential amino-acids 
NEEA (Euroclone, Milan). Hank’s balanced salt solution (HBSS) 
was purchased from Gibco, Life Technologies. Transwell permeable 
supports (24-well plates with polyester membrane 0.4 µm) were 
purchased from Corning® Costar. FITC-Dextran was purchased from 
Molecular probes, Life Technologies. Trypsin was purchased from 
(Lonza). High Pure RNA tissue Kit was purchased from Roche. 
Transcriptor First Strand cDNA synthesis kit was purchased from 
Roche. SYBR® green master mix was purchased from Aurogene (2x 
SensiFaST SYBR). Primer of TNFα, TGFβ1, IL6 was purchased 
from Diatech. 3-(4,5-dimetiltiazol-2-thiazolyl)-2,5-difeniltetrazolio 
for MTT test, NMR solutions and LPS from Escherichia Coli were 
purchased from Sigma Aldrich. 
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2.2.2 Methods	  
	  
2.2.2.1 Preparation of the nanocapsules 
 
The nano-encapsulation system consists of an oil-in-water (O/W) 
nanoemulsion Vecchione et al. [98] coated with a mucoadhesive 
chitosan derivative, namely glycol chitosan. Glycol chitosan was 
opportunely modified with a thiol moiety (Figure 2.1). Oil in water 
nanoemulsion was obtained by using a high-pressure homogenizer 
(Microfluidics M110PS), as previously described Vecchione et al. 
[106] Briefly, 5.8 g of surfactant in 24 ml of oil were used and the oil 
phase was loaded with 100 mg of curcumin dissolved in 1 ml of 
ethanol. To promote dissolution, the oil phase containing surfactant 
and curcumin was mixed by alternating a high speed blender (RZR 
2102 control, Heidolph) at 60 °C and 500 rpm to sonication with an 
immersion sonicator at room temperature (Ultrasonic Processor 
VCX500 Sonic and Materials), according to a process protocol 
previously reported Vecchione et al. [98] The curcumin loaded 
nanoemulsion was then coated with GC-NAC (glycol chitosan 
conjugated with N-acetylcysteine) or GC-RBITC-NAC (glycol 
chitosan conjugated with rhodamine B and N-acetylcysteine) by 
adding 1.5 ml of polymer solution (0.033 % (w/v) in acidified water 
at pH 4) to 1 ml of water suspensions of O/W nanoemulsion (5 % wt 
in acidified water at pH 4) under vigorous stirring. To perform the 
biological tests, a certain volume of sample was mixed with an equal 
volume of HBSS/DMEM (1:1) culture media, thus obtaining a final 
oil concentration of 1% (w/v) and a curcumin concentration in the 
O/W nanoemulsion is 0.42 mg/ml. 
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2.2.2.2 Modification of glycol chitosan with N- 
acetylcysteine (GC-NAC) 
 
Glycol chitosan was modified with a thiol moiety, exploiting the 
EDC/HOBt chemistry, as previously described Calcagno et al. [107] 
Briefly, GC (100 mg, 0.20 mmol) was dissolved in 10 ml of Milli-Q 
water, HOBt (88,9 mg) was added and pH was at first adjusted to a 
value of 4 with HCl 1M to allow complete dissolution. Then, NAC 
(400 mg) and EDC (1,916 g) were added to the solution. The pH was 
adjusted and maintained to a value of 6.8. The reaction proceeded 
overnight at room temperature. The product was purified by dialysis 
four times against water containing 1 w/v% NaCl and acidified with 
HCl at pH=3 and four times against water acidified at pH=3. Finally, 
the purified product was freeze-dried for 48 h (Freeze dryer CHRIST 
Alpha 1-4 LSC). Free thiols were determined using a colorimetric 
assay, the Ellman’s test. In particular, after reaction of thiolated 
chitosan with a DTNB solution at 25°C for 2 h, absorbance was 
registered at 412 nm using a Varian Cary Scan 100 
Spectrophotometer. GC-RBITC-NAC was obtained with the same 
procedure, by using GC-RBITC instead of pristine GC. 
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2.2.2.3 Modification of glycol chitosan with 
rhodamine B isothiocyanate (GC-RBITC) 
 
Glycol chitosan (100 mg, 0.20 mmol) was dissolved in 10 ml of 0.1 
M of acetic acid solution. After complete dissolution, a solution of 
RBITC (7 mg in 700 µl of DMSO) was added dropwise. The reaction 
proceeded over night at room temperature. Sample was then dialyzed 
(dialysis tubing with a MWCO of 6-8 kDa) against water till no dye 
was detected (using Perkin Elmer 2300 Enspire plate reader, λex= 555 
nm, λem= 565 nm). Finally, the purified product was freeze-dried for 
48 h. 
 
2.2.2.4 LbL deposition of functionalized 
polymers on polystyrene carboxylated 
nanoparticles 
Monolayer deposition. 1 ml of a water suspension (pH 4) of carboxyl 
latex beads (PS NPs, 0.5 % w/v) were added, under vigorous stirring 
for 15 min to 2 ml of a solution of GC (0.04 % w/v) in water at pH = 
4. 
 
2.2.2.5 Z-potential measurements 
 
 
The Z-potential was determined using a particle electrophoresis 
instrument (Zetasizer zs nano series ZEN 3600, Malvern Instruments 
Ltd., Malvern, U.K.). Samples were diluted up to a concentration of 
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approximately 0.025 % w/v using the proper buffer solution. The Z- 
potential analysis was carried out by setting 50 runs for each 
measurement. 
 
 
2.2.2.6 Particle size measurements 
 
Suspensions were characterized using a laser dynamic light scattering 
(DLS) instrument (λ = 632.8 nm). A detecting angle of 173° was 
used. All the samples were diluted up to a droplet concentration of 
approximately 0.025 wt% by using Milli-Q water acidified at pH 4. A 
default refractive index ratio (1.5900) and 5 runs for each 
measurement (1 run lasting 100 s) were used in the calculations of the 
particle size distribution. 
 
2.2.2.7 Modification of glycol chitosan with N- 
acetylcysteine (GC-NAC) 
 
GC was modified with a thiol moiety, exploiting the EDC/HOBt 
chemistry, as previously described Calcagno et al. [107]. Briefly, GC 
(100 mg, 0.20 mmol) was dissolved in 10 ml of Milli-Q water, HOBt 
(88,9 mg) was added and pH was at first adjusted to a value of 4 with 
HCl 1M to allow complete dissolution. Then, NAC (400 mg) and 
EDC (1,916 g) were added to the solution. The pH was adjusted and 
maintained to a value of 6.8. The reaction proceeded overnight at 
room temperature. The product was purified by dialysis four times 
against water containing 1 w/v% NaCl and acidified with HCl at 
pH=3 and four times against water acidified at pH=3. Finally, the 
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purified product was freeze-dried for 48 h (Freeze dryer CHRIST 
Alpha 1-4 LSC). Free thiols were determined using a colorimetric 
assay, the Ellman’s test. In particular, after reaction of thiolated 
chitosan with a DTNB solution at 25°C for 2 h, absorbance was 
registered at 412 nm using a Varian Cary Scan 100 
Spectrophotometer. GC-RBITC_NAC was obtained with the same 
procedure, by using GC-RBITC instead of pristine GC. 
 
 
2.2.2.8 Modification of GC with rhodamine B 
isothiocyanate (GC-RBITC) 
 
GC (100 mg, 0.20 mmol) was dissolved in 10 ml of 0.1 M of acetic 
acid solution. After complete dissolution, a solution of RBITC (7 mg 
in 700 µl of DMSO) was added dropwise. The reaction proceeded 
over night at room temperature. Sample was then dialyzed (dialysis 
tubing with a MWCO of 6-8 kDa) against water till no dye was 
detected (using Perkin Elmer 2300 Enspire plate reader, λex=555 nm, 
λem=565 nm). Finally, the purified (≅85%) product was freeze-dried 
for 48 h. 
 
2.2.2.9 Cell lines and culture conditions 
 
Human colonic epithelial cell line, CaCo-2 cells, were obtained from 
American Type Cell Culture (ATCC, USA) and were grown in 
Dulbecco's Modified Eagle’s Medium (DMEM, Gibco) 
supplemented with Fetal Bovine Serum (FBS, Sigma Aldrich), 2 
mM/l L-glutamine (Gibco), 100 IU/ml streptomycin/penicillin 
(Gibco) at 37°C with 5 % CO2 in Transwell 24-well plates (6.5 mm
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diameter, 0.4 µm pore polyester membrane insert). The cells were 
seeded at 1x105 in 0.33 cm2 and grown on polycarbonate membrane 
for two weeks. During the first week cells grows till to completely 
cover all the membrane surface, thus leading to a submerged layer; 
during the second week the upper medium is removed and cells are 
already capable to polarize, thus leading to an ALI. Medium was 
replaced every 2 days. 
 
2.2.2.10 Electron microscopy 
 
For the TEM analysis of nanocapsules, samples were first exposed to 
vapors of an OsO4 water solution (1% wt) as oil core dopant for not 
less than 4 h then, about 10 µl of the sample were spread on a copper 
grid (200 mesh with carbon membrane). After carefully removing the 
excess of solution grids were left to dry overnight.). TEM images 
were obtained using a TECNAI 20 G2 (Thermo Fisher, Eindhoven) 
with a camera Eagle 2HS. The images were acquired at 200 KV; 
camera exposure time: 1 s; size 2048 x 2048. For SEM and Energy 
Dispersive X-ray Analysis (EDX) measurements a small drop of 
solution containing nanocapsules was spread onto the surface of an 
aluminum stub covered by a glass plate. The sample was then sputter- 
coated with a thin Pt/Pd or gold layer (10 nm) in a Cressington 
sputter coater 208HR. The aluminum stub containing the Pt/Pd or 
gold -coated sample was then placed in a FEG-SEM scanning 
electron microscope and imaged using 20 kV accelerating voltage. 
For imaging analysis of cells, samples were first fixed with a sodium 
cacodylate 0.1 M in glutaraldehyde solution (2.5% wt) at room 
temperature for 2 h. Sample was washed with a solution of 0.1 M 
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sodium cacodylate - 0.1 M sucrose (3 times in an ice bath for 10 
min). Sample were then fixed with OsO4 (1% wt. in 0.1 M sodium 
cacodylate - 0.1 M sucrose) and washed again with a solution of 0.1 
M sodium cacodylate - 0.1 M sucrose (3 times in an ice bath for 10 
min). In the end samples were dehydrated by replacing the water 
solution with a series of ethanol solutions (30%, 50%, 75%, 95%, 
95%, 100%, 100%, 100% (v/v)) and dried with a Critical Point Drier 
(Leica EM CPD300). As for nanocapsules, the samples were then 
sputter-coated and imaged as previously described. 
 
 
2.2.2.11 Cell cytotoxicity experiments 
 
The cytotoxicity of the nano-emulsions was assessed on CaCo-2 cells 
using the MTT method according to the manufacturer’s instructions 
(Dojindo Molecular Technologies Inc., Rockville, MD). Cells were 
seeded in 6-well plates at a density of 200000 cells per well in 
complete medium at 37 °C in a humidified 5% CO2 atmosphere. The 
drug test was made with different concentration of  curcumin-loaded 
nano-emulsions in oil (free drug, 1%, 2%, 5% 20%) and the viability 
was evaluated at different time points (2h, 4h, 6h, 8h, 12h, 24h, 48h 
72h). At the end of the incubation period, cells were washed three 
times with PBS at pH 7.4 and incubated with 300 µl of a MTT 
solution (5 mg/ml in cell culture medium) for 4 h at 37 °C. In the end 
150 µl of DMSO were added and samples were incubated for 1h at 
37 °C. The absorbance measurements were acquired at 570 nm 
(Perkin Elmer 2300 Enspire plate reader,  λabs=570 nm). 
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2.2.2.12 Confocal imaging 
 
CaCo-2 cell monolayers cultured in transwell were washed with PBS 
solution and fixed with paraformaldehyde 4% (v/v) at room 
temperature for 20 minutes. Permeabilization was performed by 
using a 0.01% Triton solution in PBS for 5 minutes, washing three 
times with PBS and incubating with specific staining. Actin filaments 
were stained with Phalloidin-Alexa Fluor® 488 conjugate (1:50 in 
PBS). Nuclei were stained with DRAQ5™ (1:10000 in PBS). 
Cellular morphology of the CaCo-2 cells was observed with a Leica 
SP5 II laser scanning confocal microscope using a 63X oil immersion 
objective (HCX PL APO CS 63.0x1.40 OIL UV). Samples were 
observed with the following specific fluorescence channels: 
cytoskeleton (Phalloidin-Alexa Fluor® 488) λex=488 nm (Argon 
Laser) and λem=500-530 nm, nanoemulsions coated with GC-RBITC- 
NAC (rhodamine B) λex=543 nm (Helium Laser) λem=560-610 nm; 
nuclei (DRAQ5™) λex=633 nm λem=650-750 nm. Z-Stack and Y- 
Stack image series were acquired to study the localization of labeled- 
drug in the CaCo-2 cells. Section thickness was set to 0.7 µm for all 
the images. Images analysis were performed using Fiji (Image J, 
plugin) and LAS AF (Leica Applications System). 
 
2.2.2.13 Confocal analysis of CLN 
 
Samples containing curcumin loaded nanoemulsions coated with GC- 
RBITC-NAC were opportunely diluted with HBSS/DMEM buffer 
and 200 µl were put in a FD3510 dish (WPI, Germany) for 30 min to 
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allow it to adhere to the glass surface. Sample in excess was washed 
twice by replacing it with 130 µl of HBSS/DMEM solution every 10 
minutes and, in the end, with 130 µl of 5% (w/v) DABCO anti-fade 
solution (needed to avoid the bleaching effect of the Rhodamine B). 
For this analysis we used the same parameters used for cells. 
 
 
2.2.2.14 Transepithelial Electrical Resistance 
assay 
 
Transepithelial Electrical Resistance (TEER) of CaCo-2 epithelium- 
equivalent cultured in transwell was measured by using the Millicell- 
ERS (Electrical Resistence System, Millipore Corporation). The 
measured value was multiplied by the area of the membrane (1.12 
cm2) in transwell insert to obtain a TEER value expressed in Ohm x 
cm2 and blank subtracted in order to evaluate the cell monolayer 
integrity during permeation experiments. TEER test was carried out 
to examine the ability of CLN based on glycol thiolated chitosan 
(GCNAC) on the opening of the tight junctions at predetermined time 
intervals of 0h, 3h and 24 h. The experiments were done in triplicate. 
 
 
2.2.2.15 Immunofluorescence assay 
 
Tight   junctions   of   the    CaCo-2    epithelium-equivalent   
cultured in Transwell were stained using a primary antibody (ZO-1). 
Cells were washed with PBS solution and fixed with 
paraformaldehyde 4% (v/v) at room temperature for 20 minutes. 
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Permeabilization was performed using a 0.01% Triton solution in 
PBS for 10 minutes, washing three times with PBS and first 
incubating with a blocking solution (PBS, BSA 5% and Triton 
0.01%) for 2 h in a wet chamber. After washing with PBS, cells were 
incubated with ZO-1 antibody (1:50 in PBS) overnight at 4°C. 
Finally, cytoskeleton and nuclei were stained with Phalloidin-Alexa 
Fluor® 488 and DRAQ5™ solutions, as previously reported. 
 
 
2.2.2.16 Apical-to-basal permeability assay 
 
The    permeability     of     CaCo-2     epithelium-equivalent   
cultured in transwell was performed by measuring in dynamic and 
static conditions the trans-epithelial passage of the O/W 
nanoemulsion coated with GC-RBITC-NAC, of a blank sample 
(HBSS/DMEM, 1:1) and of FITC-Dextran solution (1 mg/ml diluted 
1:100 in HBSS), generally used as positive control. Cells monolayers 
were incubated for 24 h at 37°C with 5 % CO2; for dynamic 
condition a rotator at 80 rpm was used. A certain volume of 
HBSS/DMEM (1:1 V/V) was placed in the basolateral chamber in 
order to guarantee the dipping of the lower side of the membrane. 
The passage was determined by confocal imaging (Leica SP5 II Laser 
Scanning Confocal Microscope) and fluorescence emission of 
rhodamine and fluorescein, respectively (Perkin Elmer 2300 Enspire 
plate reader λex=555 nm, λem=565 nm and ). 
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2.2.2.17 Collection and NMR Analysis of 
Supernatants 
 
After 3 h incubation of Caco2 cells with CLN, supernatants and cells 
were collected and the presence of curcumin was analyzed by 
Nuclear Magnetic Resonance (NMR). NMR was performed using an 
Agilent 600 MHz (14 T) spectrometer equipped with a DD2 console 
and a OneNMR HX probe. NMR spectra were recorded with a total 
of 256 transients and a PRESAT sequence was used to saturate the 
water residual peak. Spectra analysis was performed using VNMRJ 
4.0 software. 
 
 
2.2.2.18 LPS induction 
 
Caco-2 cells were treated with a Lipopolysaccharide (LPS) solution 
(5 µg/mL) for 3 hours to induce an inflammatory response, thus 
stimulating the overexpression of pro-inflammatory cytokines like 
TNFα, IL-6 and reducing the expression of TGFβ1. After the 
inflammatory induction, epithelial cells were treated with nano- 
emulsions to evaluate the anti-inflammatory effects of curcumin. 
 
2.2.2.19 RT-PCR 
Total RNA was extracted using High Pure RNA (Roche), according 
to the manufacturer’s instruction. Synthesis of cDNA was performed 
using Kit iScript supermix according to the manufacturer’s 
instruction. Analysis of mRNA expression was determined with 
quantitative real-time PCR using 2x SensiFaST SYBR, Bioline, 
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Aurogene, 1.2 µmol primers of GAPDH as a housekeeping gene for 
normalization and 1.2 µmol primers of TNFα, IL6 pro-inflammatory 
genes and TGFβ1 anti-inflammatory gene, according to the 
manufacturer’s instruction. Sequences of primers for GAPDH: 
Primer forward: 5’-CGGAGTCAACGGATTTGGTCGTAT-3’and 
reverse:       3’-AGCCTTCTCCATGGTGGTGAAGAC-5’;      TNFα 
forward 5’-AAAGTAGACCTGCCCAGACTCGG-3’ and reverse 5’- 
GAGCACTGAAAGCATGATCCG-3’;      IL-6      Primer    forward: 
TCTCCACAAGCGCCTTCGGT and reverse: 
TGGGGCAGGGAAGGCAGC; TGF β1 forward 5’- 
CCGACTACTACGCCAAGGAGGTCAC-3’      and      reverse    5’- 
AGGCCGGTTCATGCCATGAATGGTG-3’. The relative fold 
change in gene expression was quantified using the 2-ΔΔCT method by 
normalizing the target gene expression to GAPDH and relative to the 
expression on the experimental control sample, as indicated in Figure 
7. Data are the means ± SD of triplicate samples of at least two 
independent experiments. Student’s t-test was used to determine 
statistical differences between mean values, and P < 0.01 was 
considered to be a significant difference. 
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2.3 Results and Discussions 
 
 
2.3.1 CLN formulation and analysis 
 
The presented nanocapsules consist of an oil core and a hydrophilic 
shell based on a glycol thiolated chitosan interface (Figure 2.1). The 
lipophilic nature of the oil core nanocapsules enables to load high 
amounts of lipophilic drugs, nutraceuticals like curcumin, dyes or 
contrasting agents. Due to the negative charge, the so realized oil 
core results suitable for the deposition of one or more polyelectrolyte 
layers by exploiting the LbL technique. Vecchione et al [98] In 
particular, we coated the nanoemulsion with a thiol modified glycol 
chitosan. Recently it was showed that chitosan modified with thiol 
groups determines an enhanced mucoadhesion due to the covalent 
bound with the cysteine residues of the mucus glycoproteins. This 
condition improves the permeability of epithelial-like constructs 
produced with CaCo-2 cells as proved by TEER reduction. [106, 107] 
Here, such thiolated glycol chitosan was used as coating for the 
curcumin loaded nanoemulsion (CLN). This is in agreement to the 
observations reported in the final part of this chapter (Supplementary 
results). Curcumin was chosen as model drug because of its lipophilic 
nature, its poor stability and its poor oral administration. [108] 
Curcumin was loaded at a concentration of 0,42 mg/ml of oil. 
Compared to the starting O/W nanoemulsion loaded with curcumin 
(105.1 nm and PDI = 0.060), the size of the same nanoemulsion 
coated with thiolated glycol chitosan, increased of only few 
nanometers (106.1 nm) and the PDI value remained below 0.1 
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(~0.08) (see Figure 2.2). The chitosan derivative was labelled with a 
fluorophore, rhodamine-B, which allowed to acquire confocal images 
of CLN (Figure 2.1A). 
Electron microscopy imaging of CLN (Figure 2.1B and 2.1C), with 
OsO4 stained oil assessed a narrow size distribution and nanocapsules 
size of around 100 nm. 
 
 
 
 
Figure 2.1: A) Imaging characterization of O/W nanoemulsion 
coated with GC-RBITC-NAC. B) Confocal image of CLN coated 
with rhodamine B labeled glycol chitosan; C) SEM image and D) 
TEM image of CLN stained with OsO4 vapors. Osmium staining 
strengthened the soft CLN in order to avoid collapse due to the 
vacuum of electron microscopes. 
Adapted from [124]. 
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Figure 2.2: DLS analysis of free nanoemulsion (blue line) and 
monolayer GCNAC 1% (orange line). 
Adapted from [124]. 
 
 
2.3.2 In vitro ALI model to test curcumin loaded 
nanocapsules 
 
Intestine epithelium model produced by culturing CaCo2 cells in ALI 
was used as in vitro testing platform to evaluate safety, interaction 
and anti-inflammatory activity of the proposed curcumin loaded 
nanocapsules (Figure 2.3). 
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Figure 2.3: schematic representation of air liquid interface of 
CaCo-2 equivalent epithelium in Transwell system (on the left). In 
the central insert an enlarged view of the cell monolayer grown on 
the microporous membrane. On the right the oral nano-delivery 
system consisting of O/W nanoemulsion coated with a thiolayed 
glycol chitosan. 
Adapted from [124]. 
 
 
 
We tested the biosafety of the CLN by carrying out cytotoxicity tests 
on CaCo-2 epithelium-equivalent by means of MTT test. The tested 
CLN did not induce significant suppression on the CaCo-2 cell 
viability as shown in Figure 2.4A. Moreover, the MTT data were 
confirmed by the ultrastructural analysis of polarized CaCo-2 
epithelium-equivalent that shows preservation of nuclei, 
mitochondrial integrity and polarization of CaCo-2 that formed actin- 
based brush border structures (Figure 2.4B and 2.4C). 
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Figure 2.4: Cell viability. MTT This graph shows the cell viability 
after nanoemulsion treatment. A) Untreated Control and B) treated 
with CLN (GC-RBITC-NAC). Ultrastructural analysis of CaCo2 
epithelium-equivalent at trasmission electron microscopy (TEM) B) 
untreated and C) cur treated, shows that nuclei are preserved, 
mithocondrial morphology is conserved, polarization of microvillus 
is manteined in both images. 
Adapted from [124]. 
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It is known that chitosan crosses the membrane by choosing the 
paracellular route. For this purpose, we performed TEER analysis to 
quantitatively measure the effects of the interaction mechanisms in 
terms of reversible opening of the intestinal tight junctions. [106, 
109-111] Low molecular weight FITC-dextran was used as a positive 
control to monitor the paracellular transport across intestinal 
epithelial barrier (data not shown) confirming that the CaCo-2 
epithelium-equivalent represents a functional model for the 
prediction of passive paracellular transport and for the study of drug 
absorption. [112] Chitosan’s tight junction-opening effect induced a 
reduction of TEER (19%) and consequent permeability enhancement, 
between the start time point t = 0 h (~733,6 ohm*cm2) and the end 
time point t = 3 h (~595,9 ohm*cm2). The high degree of TEER 
reversibility suggests neither cell damage nor cell layer integrity loss 
confirming that the tight junctions opening induced by the proposed 
CLN were reversible. The integrity of tight junctions was further 
confirmed by immunofluorescence analysis for ZO-1. In figure 2.5 
A-B, ZO-1 was correctly localized at intercellular level in the CaCo-2 
epithelium-equivalent as in the case of the control. 
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Figure 2.5: Barrier functionality of epithelial monolayer of CaCo- 
2 cells: 
Confocal images of Untreated Control 3h (a-b) and 3h treated with 
CLN (GC-RBITC-NAC) . This images showed a qualitative 
variation of permeability after 3 h of exposure to CLN; the effect is 
expressed by zo-1 staining. 
Quantitative evaluation of (C) TEER on CaCo2 epithelium- 
equivalent showed a variation of permeability at time point 0h , 3h 
and .24h after rinsing the monolayer with HBSS-DMEM on the 
monolayer. Data are expressed as means ± SD of three experiments. 
Adapted from [124]. 
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Figure 2.6: Confocal images of CaCo2 epithelium-equivalent: A- 
C) Y-view matching on the left ctrl and on the right 3h treated 
samples with CLN (GCNACRITCB) and B-D) on the bottom Z-view 
matching on the left control and on the right 3 h treated sample with 
CLN (GCNACRITCB). Adapted from [124] 
 
 
Furthermore, confocal imaging was used to qualitatively visualize the 
transport and localization of CLN. In Figure2.6 we showed the Y and 
Z sections of CaCo-2 equivalent epithelium acquired with confocal 
microscope. GC coating was covalently labelled with Rhodamine B. 
This labelling, together with the specific staining of the biological 
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sample, allowed to discriminate among CLN (red channel), cell 
nuclei (blue channel) and cell cytoskeleton (green channel). Confocal 
analysis highlighted the presence, the localization and the transport of 
the proposed CLN. We demonstrated that, after 3 h, CLN was 
distributed on the surface of CaCo-2 equivalent epithelium, probably 
due to the ionic interaction between chitosan and mucus layer (Figure 
2.6C-D). Indeed, the CLN appeared to be retained within the 
enterocytes as showed by the red signal located within the cells 
(Figure 2.6C-D). Hence, it can be noticed that also a transcellular 
route was chosen by the CLN. 
 
2.3.3 NMR analysis of supernatants and cells: 
 
The presence of curcumin above, inside and below the intestinal 
epithelia was evaluated by NMR (Figure 2.7). An NMR analysis was 
performed to evaluate curcumin in the upper and lower compartment 
of the in vitro model as well as inside the intestinal epithelia. In 
particular, in figure 2.7, we show the NMR spectra of CLN with no 
incubation (TQ 0 h), CLN after 3 h incubation on CaCo-2 cells 
(Upper 3 h), CaCo-2 cells after the same incubation time with CLN 
(Cell 3 h), basal compartment composed by HBSS:DMEM 1:1 and 
CLN that have crossed the intestinal barrier again after 3 h incubation 
(Lower 3 h). Spectra region between 7.3 ppm and 6.7 ppm contains 
peaks relatives to the aromatic protons of curcumin. Therefore, 
comparing the spectra of TQ, upper, cell and lower samples after 3 h 
of treatment, it is clear that curcumin decreases in upper part and 
increases in both cell and lower samples. It can be also noticed that 
the total amount of curcumin is strongly reduced in the upper solution 
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after 3 h of incubation, due to the adsorption and crossing of the cells 
monolayer. 
 
 
 
 
Figure 2.7. Aromatic region zoom from NMR spectra of CLN 
(TQ 0 h), CLN after 3 h incubation on CaCo-2 cells (Upper 3 h), 
CaCo-2 cells after 3 h incubation with CLN (Cell 3 h), basal 
compartment composed by hbss:dmem 1:1 and CLN that have 
crossed the intestinal barrier after 3 h incubation (Lower 3 h) 
Adapted from [124]. 
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2.3.4 Molecular effects: evaluation of the 
expression of anti-inflammatory and 
proinflammatory genes after curcumine 
treatment: 
 
 
In order to confirm the CLN release within the CaCo-2 equivalent 
epithelium we also evaluated their anti-inflammatory effect. As 
broadly reported in literature, curcumin is able to suppress 
inflammation via multiple pathways [95, 113,114] such as inhibiting 
the expression of various pro-inflammatory cytokines (e.g., TNFα, 
IL6, etc.) and increasing the anti-inflammatory cytokines (TGFβ1). 
To determine whether the CLN treatment could affect the 
inflammatory state of the CaCo-2 epithelium-equivalent, their gene 
expression of pro- and anti- inflammatory cytokines (TNFα, IL-6 and 
TGFβ1) was analyzed by RT-PCR. It is well known that TNFα plays 
a crucial role during acute inflammation with a wide range of 
intracellular signaling event [115]. Furthermore, TNFα activate 
several cytokines, such as IL-1b, IL-6 and IL-8 that have a role of 
amplify the inflammatory response which results in intestinal injury 
[116]. In our study, TNFα and IL-6 mRNA levels were significantly 
upregulated after LPS induction, showing that the inflammation 
model was successfully established. Several studies have 
demonstrated that LPS-stimulated CaCo-2 strongly increases the 
TNFα, IL-1b, IL-6 and IL-8 expressions in intestinal inflamed tissue 
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model [117]. In terms of the immunomodulatory action, it was 
interesting to note that in our model CLN had an effect on the LPS- 
induced TNFα secretion by CaCo-2 cells. Hence, TNFα and IL-6 
gene expression was downregulated in LPS-stimulated CaCo-2 
treated with CLN (Figure 2.8 a and 2.8b) compared with the control 
(untreated cells). It was also found that gene expression of TGFβ1, 
another central cytokines that plays a critical role in the inflammatory 
response [118], was up-regulated in LPS-stimulated CaCo-2 treated 
with CLN compared with that of the untreated cells. No significant 
differences of either the IL-8 and IL-10 mRNA level existed between 
those two groups, because a relatively higher expression level of gene 
was observed in the untreated culture (data not shown). These results 
provide further evidence that proposed CLN significantly contribute 
to reduce the inflammatory state in LPS-stimulated CaCo-2 cells. 
Based on these results, it can be assumed that the use of a modified 
chitosan as external interface of our CLN was a very good strategy to 
carry selectively the curcumin between and within the cells. 
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Figure 2.8: Molecular effects via q-PCR of differentes cytokines: 
(a) Pro-inflammatory effect of TNFα, (B) IL6 before and after CLN 
treatment in a LPS induced cells. (C) Anti-inflammatory effect of T 
GFβ1 before and after CLN treatment in a LPS induced cells. Data 
are expressed as means ± SD of three experiments. All samples have 
a p- value (< 0.01) Adapted from [124]. 
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2.4 Conclusions 
 
The beneficial properties of curcumin could play an important role 
for the treatment and the prevention of different inflammatory 
diseases. Main limitation of lipophilic molecules, like curcumin, is 
related to their low bioavailability. For this purpose, up to now a 
plethora of nanocarriers for the transport of curcumin or other 
lipophilic natural compounds have been proposed. 
In this study, we used a nanocarrier based on an oil in water 
nanoemulsion to convey curcumin by keeping its anti-inflammatory 
activity and we studied this nanocarrier from different points of view. 
In particular, we assess a favorable interaction of the nanoemulsion 
with an advanced air liquid interface (ALI) model of the intestinal 
barrier without any damage of the same. Moreover, the anti- 
inflammatory effects were investigated and proved, thus 
demonstrating that this formulation can effectively protect the drug 
from degradation. These results show the promising use of the 
proposed nanocapsules for the oral delivery of lipophilic and 
sensitive drugs like curcumin. 
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2.5 Supporting results 
 
 
2.5.1 Functionalized polystyrene 
nanoparticles as a model before O/W 
nanoemulsion particles for studying bio- 
nanointeractions 
 
2.5.2 Polymer functionalizations (GC) and (GC- 
NAC) 
 
We used polystyrenes nanoparticles (Nps) coated with GC and GC- 
NAC to evaluate how the two kinds of chitosan can affect uptake  
and distribution of the nanocarriers in different in vitro models. 
We chose polystyrene as a material, being non-degradable in the 
cellular environment and for its comproved non-toxicity to cells. 
Polymer functionalization is one of the best strategies to be taken for 
drug delivery on the target organ. The choice of chitosan as a 
polymer allows a lot of modifications, due to its structure described 
in the preview chapter. GC is a water-soluble chitosan and improves 
the crossing of epithelial tissue. 
Mucoadhesion concept came out in the early’s 80’s by Professor J.R 
Robinson at the Wisconsin University that introduced the concept of 
“mucoadhesion” as a new route to prolong the residence time of 
drugs on the ocular surface. During the time other mucosal 
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membranes have proved to be favorable to mucoadhesive polymers. 
For istance, a lot of mucoadhesive polymers were exploited for 
targeting a drug to particularly region of the body for prolonged 
period of time [119]. 
Recently, it was shown that chitosan modified with thiol groups 
determines an enhanced mucoadhesion due to the covalent bound 
with the cysteine residues of the mucus glycoproteins. 
 
 
2.5.3 In vitro distribution of 
functionalized polystyrene nanoparticles with 
glycol chitosan and thiolated glycol chitosan 
 
CaCo-2 cells seeded in transwell after one week of Air Liquid 
Interface (ALI) was used as in vitro testing platform to evaluate the 
differences in terms of crossing or distribution on intestinal cells, 
between glycol chitosan (GC) and thiolated glycol chitosan 
(GCNAC). 
As mentioned earlier, the substantial difference between the first and 
the second chitosan modification is that of crossing and remaning on 
the epithelial surface due to the presence of thiols that interacts with 
the presence of some mucus residues. We have evaluated the 
permeability of these two modified chitosan with (TEER) 
measurements and due to the presence of rhodamine B we have 
evaluated the distribution of NPS on cells by confocal analysis. 
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2.5.4 TEER measurements 
 
 
TEER of CaCo-2 was evaluated before and after 3 h and 24 h 
treatment in order to evaluate the temporary degree of TEER (Figure 
2.2.1). In fact, after 24 h tight junctions come back in the initial 
conditions. In fact, results showed in figure 2.2.1 suggest that TEER 
decreases in both GC and GCNAC. However, in the case of GC 
TEER value in average is the lowest. Thus, the first polymer (GC) is 
more permeable and water soluble so is more likely to cross the 
membrane. GCNAC stays more on the epithelial surface due to the 
disulphide bond with the thiols at the mucus cellular residues. 
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Figure 2.2.1: Transepithelial Electrical Reistence of Caco-2 before 
and after treatment with glycol chitosan (GC) and thiolated glycol 
chitosan (GCNAC). Measurement of TEER suggest that glycol 
chitosan is able to reduce more TEER value for its high solubility and 
permeability while thiolated chitosan that reduces the TEER value 
less, maybe because its mucoadhesion properties. 
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2.5.5 Confocal analysis 
 
 
In order to distinguish between two different kinds of chitosan, 
namely glycol chitosan (GC) and (GCNAC) modified glycol 
chitosan, by labeling the two polymers with a fluorophore it was 
possible to make confocal comparisons. 
In Figure 2.2.2 and 2.2.3, following the rhodamine tag (red signal) on 
the nanocapsules, it was possible to observe the different distribution 
both outside and inside the cells (nuclei in blue) associated to the two 
different chitosans. In Figure 2.2.2 polystirene nanoparticles coated 
with NAC modified glycol chitosan were distribuited mainly on the 
cell monolayer due to the strong interaction with disulphide bonds. 
Conversely, in Figure 2.2.3 it is shown a deep penetration of the 
polymers and therefore of the nanocarries in the tissue. 
Thus, these results explain the final route chosen by nanocarriers 
depending on the different chitosan. 
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Figure2.2.2. GCNAC on CaCo-2 cells. 
In this figure the distribution of the polymer elucidate the 
mucoadhesive properties of the chitosan on CaCo-2 equivalent 
intestinal epithelium. In Z and in Y-view the polymer remains on the 
surface principally and pass gradually across the cell monolayer. 
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Figure 2.2.3. (GC) on CaCo-2 intestinal epithelium equivalent. . 
Polystyrene nanoparticles were coated with Glycol RhodamineB- 
Chitosan. In Z and in Y view it is clear the deep distribution of the 
polymer. 
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2.5.6 Conclusions 
 
 
Based on LbL technique represents a very attractive tool for the 
realization of drug delivery systems (DDSs) with ideal features like 
simplicity, versatility, and nanoscale control. The aim of this part of 
research activity concerns the in vitro evaluation of completely 
biocompatible and biodegradable nanocarriers with diverse 
functionalities and different drugs. 
Starting from natural materials like soybean oil and egg lecithin as 
surfactant they were realized nanoscaled oil-core carriers in which 
hydrophobic drugs or contrasting agents have been successful 
encapsulated. 
The O/W nanoemulsions proposed by Vecchione et al. [106] possess 
relevant characteristics. Due to the use of a high pressure 
homogenizer the O/W emulsion obtained has a tunable size ranging 
from 80 to 200 nm (depending on the pressure applied and the 
surfactant used) with an excellent size distribution (PDI below 0.1). 
The so realized nanoemulsion has been used as liquid core for the 
realization of oil-core polyelectrolytes-shells nanocarriers. As for the 
liquid core, natural materials have been selected also for the 
realization of the shell, and, in particular, polysaccharides and 
polyaminoacids. [120-123] 
Starting from these conditions this research part has focused on the 
modifications of the chitosan used as coating in order to add desired 
functionalities to the final nano-vectors and besed on epithelial cells 
properties. In fact, while in Chapter 2 a nanoemulsion was loaded 
with curcumin and coated with a modified chitosan (with thiol 
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moieties) (GCNAC) is presented as an oral delivery nanocarrier 
tested on a healthy tissue and for a general evaluation of this 
particular benefical curcuma longa used as nutraceuticals. In vitro 
tests tried to clarify the routes of the nanosystem and, in particular, 
how it interacts and passes the intestinal barrier and the effect on the 
curcumin assimilation and anti-inflammatory activity. 
Instead in Chapter 3, glycol chitosan (GC) was chosen as a polymer 
due to a deep penetration of the nanocapsules and the encapsulated 
drug was PXL according to its chemoterapic properties and it was 
tested on a 3D intestinal tumoral model. 
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Abstract 
 
Cancer is a complex pathology and current 2D in vitro-based cancer 
models do not accurately recreate the complex multi-cellular, 3D 
tumour microenvironment seen in vivo; as a consequence, a 3D 
cancer model is sorely needed not only for studying the complex 
disease processes ex vivo, but especially for performing reliable 
preclinical drug screening. Additionally, there is a growing interest in 
directing therapeutics towards the stroma, rather than the cancer cells, 
as stromal cells represent a more genetically stable target that is less 
likely to develop resistance. Since the clinical oncologist’s arsenal of 
cancer therapeutics increasingly relies on biologically targeted 
compounds directed at signalling pathways related to the surrounding 
tumour microenvironment, an accurate ex vivo model that better 
replicates this microenvironmental complexity is required. 
In this perspective, it is widely regnized that the majority of in vitro 
models cannot replicate the complexity of tumoral ECM leading the 
understanding of therapeutic strategy (i.e. nanocapsules) route very 
difficult. Here, to better mimic the in vitro tumor physiology that 
includes functional and morphological changes, a novel 3D intestinal 
cancer model is proposed. We present this model as an optimal 
platform for studying antitumoral mechanism of paclitaxel 
incapsulated in an O/W nanoemulsion coated with a functionalized 
polymer. 
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Introduction 
3.1 Colorectal Cancer 
 
In the last years, colorectal cancer has become a predominant cancer 
and now accounts for approximately 10% of cancer-related mortality 
in western countries. The ‘rise’ of colorectal cancer in developed 
countries can be attributed to the increasingly ageing population, 
unfavourable modern diet, habits and an increase in risk factors, such 
as smoking, low physical exercise and obesity. The change in 
incidence is not only apparent in the rates of sporadic disease but also 
in some familial cancer syndromes. [125] 
Factors and risk conditions can be: 
- Age: the incidence of CRCs increases with the age of the 
subject. It rarely affects people under the age of 50. CRC 
cases in young adults are associated with family 
predisposition conditions 
- Familiarity: presence of first and second-degree relatives 
with familial adenomatic polyposis (FAP) or non-polypotic 
colorectal cancer (HPNCC) increases the risk of contracting 
CRC 
- Smoke: smokers are more likely to die for CRC outcomes 
than non-smokers. An American Cancer Society study states 
that "smoker women have a greater chance (40%) to die for 
CRC than non-smoking women". Similarly, "smoking men 
are more likely to die (30%) for CRC than non-smokers. 
- Diet: the high content of fat and protein in the diet increases 
the onset of CRC in relation to the carcinogenic potential of 
	   
96 
cholesterol protein catabolites. Other studies confirm the 
importance of fiber and fruit consumption as a protection 
factor. In particular, vitamins and fruit antioxidants, such as 
vitamin C, are able to protect colonic cells from oxidative 
stress. 
- Ambiental Factors: people who lives in industrialized areas 
have a greater risk of CRC development 
- Chronic inflammatory bowel processes: such as chronic 
disease and ulcerative retortitis. About 1% of CRC patients 
have a history of ulcerative retalkitis. The risk of developing 
CRC is directly related to the severity of injury to the 
intestinal mucosa and to the extension of the inflammatory 
process. The risk of developing CRC in subjects with chron 
disease is lower than those with ulcerative retouchitis. 
- Hormones: differences in the incidence and age of males and 
females can be attributed to the different hormonal pattern 
between the two sexes; In particular, the emphasis is placed 
on estrogen. The presence of conflicting data makes these 
studies still unreliable. Indeed, an increase in CRC was 
reported in women who underwent substitution therapy for 
estrogen (tamoxifen), as opposed to the hypothetical 
protective role of female hormones. 
- Presence of polyps in the colon: isolated polyps may have 
areas of proven malignancy. Conversely, in localized colon 
cancer carcinoma there are adenomaous areas due to previous 
polypoid formation. 
The site of onset of polyps is often the site of CRC's onset. Subjects 
with polyps are more likely to develop CRC than healthy subjects. 
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The more polyps are diagnosed in the subject, the greater the 
likelihood of developing CRCs (Figure 3.1). 
Polypectomy reduces the onset of CRC. Prognosis in subjects with 
colorectal cancer depends heavily on the degree of local tissue 
invasion, the infiltration of nearby organs, and the presence of lymph 
node metastases and other organs. [126-129] 
 
 
 
Figure 3.1) Colorectal neoplasia at different stages. A) A small 
sessile adenoma. B) An advanced, larger sessile adenoma. C) A 
large, dish-shaped, ulcerating sigmoid carcinoma. The tumour covers 
most of the circumference, but has not yet led to substantial 
obstruction of the lumen. Adapted from [125]. 
 
3.2 Advantages of 3D modeling vs  2D 
 
The growth and maintenance of a human tissue depend on essential 
factors such as cell-cell interactions through growth factors, 
hormones and adhesion molecules. An ECM is essential in order to 
provide mechanical support capable of regulating cellular functions 
and synthesis of biological nutrients and effectors that can support 
tissue differentiation and maturation. 2D models, while being widely 
used, are limiting the study of tumorigenic and in providing affidable 
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results during in vitro tests. [130] Despite significant improvements 
in cancer field, researchers are still working to find new and effective 
therapies against cancer. Part of the issue is the lack of suitable 
preclinical models capable of recapitulate the complexity of cancer 
disease. The colorectal cancer is a pathology that affects neoplatic 
cells as well as the entire cell surroundings. Tumor microenvironment 
is a complex milieu comprising cancer and non-cancer cells 
embedded into the ECM. [131] 
The interstitial matrix of the ECM consists of fibrillary collagens, 
proteoglycans and glycoproteins. [132] All these elements of the 
microenvironments are influenced by cancer cells and in turn 
influence tumor genesis and progression. [133] In vitro human small 
intestine models play a crucial part in preclinical drug development. 
Although conventional 2D systems possess many advantages, such as 
facile accessibility and high-throughput capability, they can also 
provide false results because of lacking physiological relevance. 
Significant progresses have recently been made in developing 3D 
human small intestine models, suggesting that more-reliable 
preclinical results could be obtained by reproducing in vitro 3D 
human small intestine model. This includes cells cultured as 
multicellular aggregates (spheroids) and cells embedded into natural 
(such as Matrigel, Fibrin or Collagen) or synthetic matrices (such as 
PLG, PLA, PEG) generally cultured in multiwell or into microfluidic 
devices. [134] Lot of them do not recapitulate the actual environment 
in which cancer cells are found in vivo. In fact, spheroids are 
characterized by low collagen [135] and natural or synthetic matrices. 
This system effectively does not replecate the physiological 
complexity of the microenvironment typically associated with 
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advanced carcinoma in vivo. Another recent culture system involves 
cell seeding on fibroblasts 3D matrices but these are commonly 
murine. [136-137] 
In order to develop new target strategies, it is neecessary to consider 
the importance of the ECM. Jiajie Yu et al. [138] affirm that 3D 
human intestinal model has the potential to facilitate drug screening 
and drug development. Significant progress has recently been made 
in developing 3D human small intestine models, suggesting that 
more-reliable preclinical results could be obtained by recreating the 
3D intestinal microenvironment in vitro. Thus, it has always been 
known that in vivo animal models too often fail to represent the 
pathology of human tumors, for this purpose the need to develop 
several in vitro models is high. 
 
3.3 In vitro 3D tumoral intestinal model for drug 
delivery tests 
The models generated through recent 3D culture systems can meet 
the basic requirements for recreating a human tissue and being used 
as preclinical tumor models for drug delivery or drug release. 3D 
cellular models can accurately reproduce the tumor micro- 
environment and mimic the regulatory mechanisms that cross 
between tumor and stroma. The 3D cell cultures exhibit peculiar 
molecular characteristics that are also significantly different from 
monolayer cultures and they are closer to the structural structure of 
the tissue in vivo. For this reason, when the object of the study is a 
tumoral tissue, this kind of tissue architecture shows that epithelial 
tumor cells undergo variations in shape and polarity, typically 
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associated with in vivo tumor progression. [139] Currently, the most 
popular 3D model is a multicellular tumor spheroids (MCTS), or 
organoids and tumoroid. The definition of these terms is very 
controversial in literature. In fact, they consist of tumor cells or a co- 
culture of tumor and thrombotic cells that acquire a spherical 
symmetry organized in three-dimensional order. Spheroids are 
generally produced by stabilized cell lines that aggregate in a 
homotypical manner and exhibit morpho-physiological 
characteristics that favor complex cell-cell and cell-matrix 
interactions. [140] These characteristics make them comparable to 
vascular tumor regions and / or micro-metastases in vivo. Tumor cells 
within the spheroid reproduce the same concentric arrangement and 
at the same time have a growth pattern similar to solid tumors in the 
non-vascular initial space. These features make multicellular tumor 
spheroids a system closer to the in vivo tumor structure and make 
them an excellent alternative to the study of different tumors. Due to 
their peculiarities they are a good model for testing antitumor drugs 
or to evaluate the gene expression of tumor cells during neoplastic 
development. Although the spheroid method is a promising approach, 
it has some disadvantages. In the first place, the spheroids form large 
aggregates that show a central necrotic core and this technique not is 
suitable for large scale and for a long-term studies. 
Recently, Brancato et al. [141] demonstrated that spheroid and 
microtissue posses different “tissue mimicking capability”. They 
prove that 3D system promotes the assembly of ECM that better 
replicates the functional differences existing in vivo between normal 
and cancer-activated tissue in terms of cell growth, cell metabolim, 
metabolic and mechanical microenvironment and ECM composition. 
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For this reason, the 3D model would increse the predictive potential 
of both tumor-on-chip system, and drug screening platform (figure 
3.4). Another good revolution for intestinal 3D tissue realization was 
made by Sato et al. [142] successfully cultured murine epithelial 
organoid from single Lgr5+ intestinal stem cell (ISC) in vitro. 
Subsequently, human pluripotent stem cell (hPSC)-derived intestinal 
organoid (HIO) [137] and organoids derived from human normal and 
diseased biopsy samples were developed. [143] These 3D, self- 
organized, physiologically relevant cellular structures can be grown 
long-term and remain genomically stable. 
These systems have already proven to be useful in studies of GI tract 
development, homeostasis, human-microbiome symbiosis, and 
pathogenesis and for drug delivery screening. 
Here, we propose the realization of human 3D colorectal cancer 
tissue as platform for study the effects of enginereed paclitaxel- 
loaded nancapsules. By exploiting the affinity with the cellular 
model, nanoapsules can releases in a specific and deep way the drug 
in this case paclitaxel, overcoming a whole set of limitations of 
conventional anticancer therapy. 
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Figure 3.4: Masson Trichrome images of NF-lTP (A–C), CAF-lTP 
(D–F), NF-sph (G–I) and CAF-sph (L–N) at Day 4, Day 8 and Day 
12. Collagen in blue, cell nuclei in purple. Initial gelatin microsphere 
when present appear stained in red/brown. Scale bar is (A–C) 100 lm, 
(D–N) 50 lm. Adapted from [141]. 
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3.4 Our approach: tissue modules realization 
 
 
Our approach is proposed as a bottom up method to build up 3D 
tissue constructs in vitro by using microtissues (µtP) as functional 
building units. µtP modules have been obtained by means of dynamic 
cell seeding of fibroblasts on porous gelatine microcarriers using a 
spinner flask bioreactor as depicted in step 1 of (figure 3.2A). Several 
studies demonstrated that this particle cultivation technique is more 
effective than cell culture on flat substrates such as culture dishes. 
[143] Under optimal culture conditions, cells were able to adhere, 
proliferate, and, in particular, synthesize ECM components to form a 
thin layer of de novo-produced tissue around the microbeads. This 
micrometric tissue wrapped around and within the porosity of the 
scaffold constitutes micrometric tissue precursors (µtPs) for further 
large-tissue construction. [144] The process for µtP formation 
consisted of a dynamic cell seeding performed in a spinner flask 
bioreactor, which was loaded with cells and porous gelatine 
microbeads in the ratio of 11-13 cells per microbead and operated at 
20 rpm for 10 days. The disappearance of free cells from the 
inoculated spinner cultures was considered to indicate the attachment 
of cells to the microcarriers. 
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Figure 3.2. Description of 2 STEP process used to generate 3D 
tissues in vitro. cell seeding and micro-scaffold colonization at an 
early time; ECM synthesis and formation of small aggregates named 
µTP; (A) fusion and assembly of µTP to produce large 3D tissues. 
 
 
3.4.1 µTPs assembly and maturation chamber 
 
To obtain a single and compact macro tissue of the desired shape and 
thickness, the µTP suspension was withdrawn from the spinner flask 
and transferred and cultured in an assembling chamber (Figure 3.3B). 
The assembling chamber has a sandwich-like structure (Figure 
3.3Ba), in the middle of which there is a silicon mould with four 
empty spaces (1 mm in thickness, 10 mm in diameter, Figure 3.3Bb), 
where the µTPs assembly takes place. The silicon mould is delimited 
on both the top and bottom sides by two stainless steel rigid grids 
(Figure 3.3c) characterized by a porous mesh (18 lm) that is able to 
retain the µTPs. Two polytetrafluoroethylene (PTFE) rings (Figure 
3.3Bd) are placed on the grids on both sides of the system and are 
fastened to each other by means of stainless steel screws, which close 
the system and ensure that the µTPs are retained. The system is 
autoclavable in each part. The µTP suspension was transferred from 
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the spinner flask to a 50 ml Falcon centrifuge tube and, after settling, 
transferred by pipetting into the empty spaces of the silicon mould of 
the assembling chamber (Figure 3.3B) to allow the assembly. 
Furthermore, the assembling chamber was placed in a spinner flask 
and filled with culture medium. The spinner was operated at 50 rpm 
and the medium was exchanged every 2 days. After 4-5 week of 
culture the assembling chamber was opened and the biohybrids were 
collected for different analysis. 
 
 
 
 
 
Figure 3.3: A bottom-up approach was proposed to build up 3-D 
tissue constructs in vitro by using µTPs as functional building units. 
The process philosophy is schematized. Adapted from [144]. 
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3.4.2 Realization of 3D human equivalent model 
 
Seeding human epithelial cells like keratynocytes, Caco-2, Hct116, 
and some other types of epithelial cells on this kind of matrix allowed 
obtaining a functional tissue equivalent model in which it is possible 
to generate structures in vitro resembling the in vivo features. [145] 
 
3.4.3 O/W Nanoemulsion loaded with Paclitaxel 
for drug delivery test on 3D intestinal diseased 
model 
PXL is a common chemotherapeutic that has been used clinically for 
many years to treat ovarian, breast, lung, and pancreatic cancer. It is 
also an approved chemotherapeutic in the UK for ovarian, breast, 
lung, bladder, prostate, and other types of solid tumors as well as 
melanoma and Kaposi’s sarcoma. [146] Recent studies have shown 
the effects of PXL also in coloncancer. The mechanism of action of 
PXL involves interference with the process of normal breakdown of 
microtubules during cell division, causing apoptosis in the treated 
cells. [147-149] The solubility of PXL hinders its application in the 
clinic. In addition, PXL can cause some side effects such as 
hypersensitivity reactions, myelosuppression, and peripheral 
neuropathy. [150] This makes the nanodrug delivery system a useful 
tool to assist with PXL solubility and delivery. Lipid nanocapsule- 
loaded PXL was also shown to be more effective for oral 
administration with enhanced bioavailability. [151] Nanoemulsion is 
another attractive way to deliver the hydrophobic drugs such as PXL, 
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and some studies have demonstrated that nanoemulsion loaded PXL 
can overcome drug resistance [152-153] increase cellular uptake, 
[154-155] and enhance cytotoxicity and apoptosis in different cancer 
cells. [156] In colorectal carcinoma, several previous studies have 
shown that PXL could inhibits tumor cell growth by regulating 
glutaminolysis in colorectal carcinoma cells. [157] Mounting 
evidence indicates that altered glutamine metabolism in cancer cells 
has critical roles in supporting macromolecule biosynthesis, 
regulating signaling pathways, and maintaining redox homeostasis, 
all of which contribute to cancer cell proliferation and survival. Thus, 
intervention in these metabolic processes could provide novel 
approaches to improve anti-cancer treatment. [158] Our nanocapsules 
are able to reduce cells invasion and metastatis in colorectal cancer, 
due to their capability to increase PXL solubility and enanche the 
crossing because of functionalized polymer modification (GC). 
 
 
3.2 Materials and methods 
 
 
1-hydroxybenzotriazole hydrate (HOBt), N-acetyl-L-cysteine (NAC), 
Rhodamine B isothiocyanate (RBITC), paraformaldehyde and 
curcumin (from Curcuma Longa Turmeric), powder, m.w. = 368.38 
g/mol) were purchased from Sigma-Aldrich. (GC) was purchased 
from Wako Chemicals. 1-(3-dimethylaminopropyl)-3-ethyl- 
carbodiimide hydrochloride (EDC) was purchased from Iris Biotech. 
CaCo-2 cells were obtained from American Type Cell Culture 
(ATCC, Usa). Dulbecco’s Modified Eagle’s Medium (DMEM, 
Gibco, Life Technologies), supplemented with 10% fetal bovine 
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serum (FBS, Sigma Aldrich), 1% penicillin/streptomycin and 1% L- 
glutamine (Lonza, Milan) and 2% nonessential amino-acids NEEA 
(Euroclone, Milan). Hank’s balanced salt solution (HBSS) was 
purchased from Gibco, Life Technologies. Transwell permeable 
supports (24-well plates with polyester membrane 0.4 µm) were 
purchased from Corning® Costar. FITC-Dextran was purchased from 
Molecular probes, Life Technologies. Trypsin was purchased from 
(Lonza). High pure RNA tissue kit was purchased from Roche. 
Transcriptor First Strand cDNA synthesis kit was purchased from 
Roche. SYBR® Green Master mix was purchased from Aurogene 
(2x SensiFaST SYBR). Primer of GLS, SLC1A5, SLC7A11 was 
purchased from Metabion. 
 
3.2.1 Cells culture 
 
Human dermal fibroblasts (HDFs) were extracted from healthy 
foreskin or breast biopsies and cultured in enriched MEM: MEM 
(Microtech L0440-500) with 20% of FBS (Sigma Aldrich), 2% of 
Non-Essential Aminoacids (EuroClone ECB3054D), 1% of L- 
Glutamine (Lonza 17-605E) and 1% of penicillin/streptomycin 
(Microtech L0022-100), until passage 4/7. 
InMyoFibroblasts were seeded into a flask and cultured with the 
apposite supplemented medium SMBM/SMGM by Lonza. 
 
3.2.2 HDFs and inMyoFibroblastas source 
 
Cells were extracted from human tissue biopsies surplus obtained by 
“Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione 
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(AORN) A. Cardarelli/Santobono/Pausillipon at Urology and 
Biotechnology Centre - AORN” according to the project “Realization 
of human skin equivalent in vitro” after approval of ethical 
committee. Even if, InMyFibroblast were pruchuased by Lonza. 
 
 
 
3.2.3 Micro-scaffold production 
 
Gelatin porous microbeads (GPMs) were prepared according to a 
modified double emulsion protocol (O/W/O). GPMs were stabilized 
by crosslink reaction with glyceraldehyde (GAL) (SIGMA-G5001), 
in order to make them stable in aqueous environment at 37 °C, as 
previously described. GAL at 4% w/w of the microbeads was used to 
perform all the experiments. 
 
3.2.4 Micro-tissues (µTPs) production 
 
About 13 HDFs p5/8 were seeded for each bead. Cells were cultured 
into spinner flask bioreactor (Integra) in continuous agitation (30 
rpm) after 6 hours of intermitting stirring regime in order to promote 
cell seeding (30 min at 0 rpm, 5 min at 30 rpm). The culture medium 
was enriched MEM plus Ascorbic Acid (2-O-α-D-105 
Glucopyranosiyl-L-Ascorbic-Acid TCI; Cf: 0.5mM). µTPs were 
cultured for 9 days before the phase of assembly in order to guarantee 
the initial collagen synthesis. 
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3.2.5 Intestinal equivalent model production 
 
During the microtissue assembly the µTPs suspension was transferred 
from the spinner flask to a 50 ml Falcon centrifuge tube and, after 
settling, transferred by pipetting into the maturation chamber to allow 
their molding in disc-shaped construct (1 mm in thickness, 8 mm in 
diameter). During the filling procedure, the maturation chamber was 
accommodated on a device connected with a vacuum pump to make 
the process faster and to assure that any bubble was in the maturation 
space. The assembling chamber was a sandwich-like structure with in 
the middle a silicon mold with empty spaces (disc shape: 1 mm in 
thickness, 8 mm in diameter; wire shape: 1 mm in thickness, 5cm 
length) for the µTPs housing. The silicon mold was delimited on both 
the top and bottom sides by two stainless steel rigid grids 
characterized by a porous mesh (18 µm) that was able to retain the 
µTPs and to guarantee the passage of nutrients and waste products. 
Two polytetrafluoroethylene (PTFE) rings were placed on the grids 
on both sides of the system and were fastened to each other by means 
of stainless steel screws, which close the system. The assembling 
chamber was placed on the bottom of a spinner flask (Bellco 
biotechnology code 1967- 00050) and completely surrounded by 
culture medium. The spinner was operated at 30 rpm. The culture 
medium was enriched SMDM and EMEM plus ascorbic acid. After 
4-5 weeks of culture the assembling chamber was opened and 
biohybrids were collected. 
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3.2.6 Epithelial cell seeded on biohybrids 
 
For the production of the 3D healty model, Human colonic epithelial 
cell line, CaCo-2 cells, were obtained from American Type Cell 
Culture (ATCC, USA) and were grown in Dulbecco's Modified 
Eagle’s Medium (DMEM, Gibco) supplemented with fetal bovine 
serum (FBS, Sigma Aldrich), 2 mM/l L-glutamine (Gibco), 100 
IU/ml streptomycin/penicillin (Gibco) at 37°C with 5 % CO2. The 
cells were seeded at 1x105 on 8 mm biohybrids and grown into a 
Transwell insert were biohybrids were tmoved on polycarbonate 
membrane for three weeks. During the first week cells grows till to 
completely cover all the biohybrid surface, thus leading to a 
submerged layer; during the second and third week the upper medium 
is removed and cells are capable to polarize, thus leading to an ALI. 
Medium was replaced every 2 days. While for the realization of a 
tumor 3D model the HCT116 were seeded at the same concentration 
and the same time were respected. The difference is the medium that 
was RPMI purchuased by Lonza and supplemented with fetal bovine 
serum (FBS, Sigma Aldrich), 2 mM L-glutamine (Gibco) 100 IU/ml 
streptomycin/penicillin (Gibco) at 37°C with 5 % CO2. 
 
 
3.2.7 Immunofluorescence on the 3D sample 
 
 
Sample were fixed in 4% paraformaldehyde (P61148-500g Sigma 
Aldrich) for 30’ at RT and washed in PBS. They were permeabilized 
using 0,1% Triton (Triton® X-100 T9284-100ML Sigma) in PBS for 
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5’ at RT, washed in PBS and blocked in 1%BSA (A9418-100G 
Sigma) for 1h at RT. Samples were stained with Rhodamine Ulex 
Europaeus Agglutinin I (UEAI Vector Laboratories RL-1062) at a 
final concentration of 20µg/ml in blocking solution, in order to mark 
the endothelium, overnight (ON) at 4°C in the dark. The morning 
after, samples were washed with PBS1X. The nuclei of all the cells 
were stained with Sytox Green (Invitrogen S7020) for 20’ at RT. 
Samples were fixed in PFA 4% and after washed for three times in 
PBS. After the samples were moved into a fluorodish 23mm and 
incubated for 1h with different concentrations of TBE and PBS 20% 
40% 60% 80% and the last incubation with TBE 100% overnight at 
RT. Samples were investigated into the same fluorodish by Confocal 
Leica TCS SP5 II. 
 
3.2.8 Histology on paraffin sections 
 
Samples were fixed in Formalin 10% (HT501320 Sigma) for 1h at 
Room Temperature (RT) and washed in PBS (P4417-100TAB 
Sigma). They were dehydrated in Ethanol from 75% to 100% and 
treated with xylene (A9982 ROMIL) before the inclusion in paraffin. 
Tissue slices thick 7µm were cut using a microtome (Thermo 
Scientific HM 355S) and then deparaffinized using xylene. Sections 
were hydrated in ethanol from 100% to 75%, washed in water and 
stained using Hematoxylin/Eosin (Bio Optica W01030708). The 
sections were mounted with Histomount Mounting Solution (Bio 
Mount HM 05-BMHM500 Bio-Optica) on coverslips and the 
morphological features of µTPs were observed with a light 
microscope (Olympus, BX53). 
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3.2.9 Second harmonic generation signal 
 
For SHG imaging samples were investigated by confocal microscopy 
(TCS SP5 II Leica) combined with a MPM where the NIR 
femtosecond laser beam was derived from a tunable compact mode- 
locked titanium: sapphire laser (Chamaleon Compact OPO-Vis, 
Coherent). Two-photon excited fluorescence was used to induce 
second harmonic generation (SHG) and obtain high-resolution 
images of unstained collagen structures. The samples were observed 
by using λex = 840 nm (two photons) and λem=415-425 nm. The SHG 
images were acquired with a resolution of 12 bit, 512x512 pixel by 
using a 25X water immersion objective (HCX IRAPO L 25.0X0.95 
Water, n.a. 0.95). 
 
 
3.2.10 Molecular analysis 
 
 
Biohybrid with HCT116 were weighed, cut and treated with 
2,5mg/ml collagenase A (ROCHE) for 30 minutes. Samples in lysis 
buffer were placed into 2ml Eppendorf with a stainless-steel ball for 
mechanical digestion on a vortex. RNA extraction was performed by 
means of the high pure RNA tissue kit (ROCHE 12033674001) 
according to manufacturer’s protocol. Lysates were centrifuged into 
high pure filter tube. The flow through was discarded and samples 
were incubated in presence of DNase and DNase incubation buffer 
for 15 minutes at RT. Washing buffer 1 with ethanol was added and 
samples were centrifuged for 10 seconds at 10.000 rpm and flow 
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through was discarded, so for washing buffer 2. After a second wash 
in buffer 2, samples were centrifuged for 2 seconds at 13.000rpm. 
Finally, RNA was eluted in 50µl of elution Buffer after centrifugation 
for 1 minute at 10.000rpm. RNA was quantified by means of 
spectrophotometer (Eppendorf Bio Photometer). 100ng of RNA were 
retro-transcribed using iScript™ reverse transcription supermix 
(Biorad 1708840). 4µl of super-mix and water were added to samples 
up to a final volume of 20µl. The complete reaction mix was 
incubated in a thermal cycler using the following protocol: 5 minutes 
at 25°C, 30 minutes at 42°C and 5 minutes at 85°C. 
Real Time PCR was performed using BIORAD CFX96 Real-time 
system C100 Touch Thermal cycler. 2,5µl of cDNA were mixed with 
iQ™ SYBR® Green Super-mix (Biorad 170-8880), 0.6µl of forward 
and 0.6 µl reverse primers (from stock solutions 100µM) and water to 
a final volume of 10µl. All quantifications were normalized with the 
GAPDH mRNA level, then the fold induction was calculated by the 
ΔΔCt method. 
 
 
 
 
 
Table 3.1: Primer sequences of GLS, SLC7A11 and SLC1A5 
genes. 
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3.2.11 Statistics 
 
Experiments were performed in triplicate. Data are expressed as 
mean ± SD. Differences between groups were determined using the 
statistic test ANOVA Tukey HSD test. Significance between groups 
was established for p value<0.01 or p value<0,05. 
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3.3 Results and discussions 
 
 
3.3.1 3D human colorectal cancer intestinal 
epithelial model 
 
Nanotechnology-based systems such as nanocapsules, play an 
important role by enanching the efficacy for cancer therapy. The 
realization of 3D human colorectal cancer is really important for a 
good study of drug delivery and drug release. This kind of in vitro 
model are able to improve, more in detail, the influence of (ECM) in 
a molecular pathways invoved in cancer. The realization of disease 
3D human intestinal model is finalized as an innovative platform for 
in vitro drug release,	   by exploiting the affinity with the cellular 
model, in a specific and deep way the drug, paclitaxel, overcoming a 
whole set of limitations of conventional anticancer therapy. 
 
3.3.2 HD-µTP assembly assessment 
 
The spinner flasks were loaded with 3,5 x106 cells and 54 mg of 
microbeads, corresponding to 15 cells per bead with an initial cellular 
density of 70,000 cells/ml and in a minimal volume of 50 ml. The 
first 8 h of the seeding phase were characterized in static mode, after 
8 h the spinner flask goes overnight in an intermittent stirring to 
improve the cell-to-bead distribution and to obtain a lower proportion 
of unoccupied beads. [159] The disappearance of free cells from the 
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inoculated spinner cultures was considered to indicate the attachment 
of cells to the microcarriers. Only in this condition the spinner flask 
can go in a dynamic mode at 30 rpm for 10 days. Before proceeding 
with the loading of HD-µTP in the blank spaces of maturation 
chamber it was necessary to evaluate the aggregation of HD-µTP and 
deposition of an initial collagen matrix around and inside 
microcarriers. At 10 days of dynamic culture in spinner flask, HD-
µTP appeared as 3D small compact aggregates composed of cells, 
evenly distributed around and inside the microbeads (Figure 3.4a). 
Masson Trichrome staining revealed the histological composition of 
HD-µTP, which aggregates of porous microbeads were surrounded 
by collagen (blue) and cells (violet) that proliferated exploiting the 
maximal available surface given by the interconnected porosity of 
GMPs (Figure 3.4b). Collagen deposition was confirmed by SHG 
signal (grey) (Figure 3.4c). 
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Figure 3.4. HD-µTP analysis. a) HD-µTP at optical microscope 
(Mag 4X); b) Masson Trichrome staining which showed cells around 
and inside microbeads (violet) and the ECM assembled (blue) 
surrounding 3D cell aggregates; c) SHG signal: collagen fibers were 
assembled around cells and held together microscaffolds and cells in 
a 3D µTP construct. Bars in a, is 100 µm; bar in b) Mag. 20X c) is 50 
µm. 
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3.3.2 3D human intestinal stroma 
characterization 
After HD-µTP assembly in the maturation chamber (Figure 3.5a and 
3.5b), at the end of about 4 weeks of culture in the bioreactor (Figure 
3.5c), we obtained a homogeneous and compact 3D human intestinal 
stroma equivalent model that preserved the shape and size after the 
removal from the chamber. 
 
 
 
 
 
Figure 3.5 : Intestinal stroma construction step by step 
(A) HD-µTP of 10 day of culture loaded in the maturation chamber; 
(B) maturation chamber sealed with grids, PTFE rings, screws and 
bolts; (C) bioreactor loaded maturation chamber sealed; (D) 3D 
intestinal equivalents obtained after 4 weeks of maturation in 
bioreactor. 
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3.3.3 3D human intestinal equivalent 
characterization 
In order to develop a 3D full thickness human intestinal diseased 
model, human stroma equivalent tissues were extracted from 
chambers and prepared for HCT116 or CaCo-2 cells seeding. (Figure 
5d) 3D full proliferation and differentiation of intestinal epithelial 
cells were cultured in transwell inserts in a traditional condition. 
During the submerged phase, 3D-intestinal equivalent were fully 
covered by medium, in order to allow cellular proliferation. After 7 
days, samples were places in (ALI) favouring the cell polarization. 
The ALI time is around 10 days. After this period 3D samples are 
ready to some drug tests. (Figure 3.6) 
 
 
 
 
 
 
Figure 3.6: 3D human intestinal equivalent in a transwell insert 
after intestinal hct116 colorectal cancer cells seeding. 
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3.3.4 Healthy vs. tumoral 3D human intestinal 
model 
Histology analysis allowed us to evaluate the distribution on the 
equivalent human stroma of the two types of cells. 
CaCo-2 intestinal that mimic a healthy phenotype and which are on 
the surface of the equivalent human stroma are placing in an ordered 
and polarized epithelial cell layer. (Figure 3.7A) In the second image 
instead, the HCT116 cells, invasive cells of colorectal carcinoma are 
only partially on the epithelial surface, a lot of cells tend to migrate 
and invaded the extracellular matrix.(Figure 3.7BD) This type of 
analysis was also performed in the confocal microscope. Here, it is 
clear how cells are distributed by invading the stroma.(Figure 3.7C) 
These results confirmed what happens under in vivo condition, that is 
a principal charachteristic of colorectal carcinoma. 
 
A) B) 
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Figure 3.7: 3D tumoral intestinal model analysis: (A) scale bar 200 
µm and (B) Mag 20x respectively histologic and confocal images, it 
is clear that HCT116 colorectal carcinoma cells are able to reach the 
(ECM) and migrate for tumor invasion as in vivo conditions (C) scale 
bar 100 µm (D) Mag 40x. 
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3.3.5 In vitro 3D intestinal diseased model as 
platform to test paclitaxel loaded nanocapsules 
 
In this study the aim was a deep penetration of the nanocapsules in 
the tissue, we used O/W nanoemulsion coated with glycol chitosan 
instead of modified glycol chitosan to avoid strong interaction 
between nanocapsules and mucus layer. This is in agreement with the 
observations previously described in chapter 2 (Supplementary 
results). These nanocapsules were loaded with paclitaxel and tested 
on the 3D intestinal disease model. After complete distribution of 
HCT116 seeded on 3D intestinal equivalent stroma, the test starts. 
The O/W nanoemulsion was loaded with 5µM paclitaxel with an 
encapsulation efficacy (> 95%) and coated with a specific designed 
polymer able to promote the permeability and solubility of the 
nanoemulsion through extracellular matrix in order to reach the 
HCT116 cells that after seeding invaded the human stroma quivalent. 
When the 3D intestinal diseased model reaches the optimum 
conditions, approximately after ten days, the test may begin. The 
paclitaxel loaded nanocapsules were suspended 1:1 in a poor colture 
medium: HBSS and put in contact with 3D intestinal diseased model 
housed in a transwell insert were a PDMS mold was used like sealed 
chamber, in order to confine the suspension of nanocapsules 
completely on the surface. (Figure 3.8) In this way it is avoided that it 
falls into the basolateral compartment. After 3h in the incubator at 
37°C and 5% of CO2 sample were rinsed 3 times with PBS and 
processed for different analysis. 
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Figure 3.8: 3D intestinal tumoral model before the test. The 
sample was housed in a transwell insert with PDMS sealed chamber 
in order to confine the drop of paclitaxel loaded nanocapsules 
 
 
3.3.6 Confocal imaging characterization of 
paclitaxel loaded nanocapsules and molecular 
effects: evaluation of the expression of 
glutaminolysis-related genes 
 
Furthermore, confocal imaging was used to qualitatively visualize the 
transport and localization of paclitaxel loaded nanocapsules. (In 
Figure 3.9AB) we showed a 3D sections of 3D intestinal diseased 
model acquired with confocal microscope and elaborated with a 
software (Las-af X). GC coating was covalently labelled with 
Rhodamine B. This labelling, together with the specific staining of 
the biological sample, allowed to discriminate among paclitaxel 
loaded nanocapsules (red channel), cell nuclei (green channel) and 
collagen (grey channel). Confocal analysis highlighted the presence, 
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the localization and the transport of the proposed paclitaxel loaded 
nanocapsules. We demonstrated that, after 3 h, paclitaxel loaded 
nanocasules was distributed in the huma stroma equivalent, thanks to 
the presence of glycol groups that improve the capability of chitosan 
to permeate the tissue (Figure 3.9B). Hence, it can be noticed that 
they can cross the epithelium and rise the cells that have been invated 
the stroma. In order to confirm the paclitaxel loaded nanocapsules 
release paclitaxel, we also evaluated their anti-tumoral effect. 
Precisly we have evaluated the ability of paclitaxel to inhibits tumor 
cell growth by regulating glutaminolysis in colorectal carcinoma 
cells. To maintain a robust increase in nutrient uptake, in addition to 
increasing glycolysis, tumor cells commonly activate glutaminolysis. 
GLS, SLC7A11 and SLC1A5 genes play an important role in 
glutamate transport and metabolism. [158] After incubation, we 
evaluated the expression of glutaminolysis-related genes GLS, 
SLC7A11 and SLC1A5 that were significantly decreased in the 
colorectal carcinoma cells treated versus control that was treated with 
an empty O/W nanoemulsion (Figure 3.10). 
Our results show that when the nanocapsules across the epithelia and 
go through the ECM they are capable of releasing PTX, which in 
turn, significantly decreases the expression level of glutaminolysis- 
related genes. 
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Figure 3.9: Confocal analysis of 3D intestinal tumoral model. 
3D view of the samples: A) on the left ctrl and B) on the right 3h 
treated samples with Paclitaxel loaded nanocapsules. 
In the treated samples nanoparticles across the 3D intestinal diseased 
model reaching also the cells that invaded the stroma. 
Scale bar 100µm 
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Figure 3.10: mRNA expression of glutaminolysis-related genes. 
Gene expression levels detected by quantitative real-time PCR assay 
after 3h treatment. The mRNA expression of GLS, SLC7A11 and 
SLC1A5. Data represent the means ± SD. 
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3.4 Conclusions and future perspectives 
 
 
In conclusion, we developed a 3D complex tumoral intestinal in vitro 
model that due to the well-organized stromal micro-environment, 
represents a good platform for drug delivery systems. Therefore, it 
might be a promising tool for more predictive preclinical testings 
with pharmaceutical substances, probiotic active organisms, or 
chemoterapic agents based on tissue features. 
The biological complexity of 3D tissue entails high requirements 
regarding applicable culture technique. In this context, 3D in vitro 
models can more realistically reproduce an organ target due to their 
complexity. According to the “3Rs” guiding principles for more 
ethical researches, 3D in vitro models can overcome the limitations 
of animal models, thus reducing the need for in vivo testing. 
Therefore, these models can offer a valid possibility for closing the 
gap between animal testing and drug administration to human 
subjects in clinical trials. Indeed, the better is the design of 3D 
models, the more significant is the reduction of the number of 
animals used for drug delivery systems studies in vivo. 
In fact, in this thesis it was shown how is possible to move from 2D 
to 3D platforms for drug testing. The fact is that we are effectively 
able of creating both healthy and pathological cell assemblies. 
In the light of this, the tissue engineering field is moving forward to 
its ultimate goal where organotypic systems can fully replace animal- 
based in vivo experimenting. 
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